



Government of Pakistan
Ministry of National Health Services, Regulations & Coordination
Drug Regulatory Authority Of Pakistan
Health & OTC Products Division (Non-Drugs)

Islamabad, the 24th February, 2022

“SAY NO TO CORRUPTION”

Subject: Submission of deficient information / documents

The applications of following applicants were placed before the Enlistment Evaluation Committee (EEC) in its 95th meeting held on 16th September, 2021 and the same have been deferred being deficient of the information / documents as specified in column (3) of the Table below which may be furnished within 20 days of uploading of this letter on official website of DRAP along with soft data as per **Annexed Format** at the end of this letter/document. Replies received after given time will not be entertained:-

S.No (1)	Brand name (2)	Decision (3)
(For Export Purpose Only)		
M/s Davis Pharmaceuticals Lab (Consumer Division), 1st floor, 121-Industrial Triangle Area, Kahuta Road, Islamabad (E. No. 00370)		
1.	Davicolin Drop	Deferred for submission of Fee for drop dosage form and for clarification since Citicoline Sodium registered as drug
M/s Hamdard Laboratories (Waqf) Pakistan, Karachi		
2.	Hamdard Fe-Lozenges	Deferred for clarification and confirmation of lozenge section
M/s Herbion Pakistan (Pvt.) Ltd. located at the address Plot # 30, sector 28, Korangi Industrial area, Karachi		
3.	Linkus Throat Spray:	Deferred for clarification of dosage form and for unit dose dispensing
M/s. BM (Private) Limited.(E.No 00041)		
4.	BM's Buthus australis (Potency)	Deferred because The applied formulation contains poisonous Buthus australis and safety profile of product is required
5.	BM's Cenchris contortrix (Potency)	Deferred because The applied formulation contains poisonous Cenchris contortrix and safety profile of product is required
6.	BM's Coccinella septempunctata (Potency)	Deferred because The applied formulation contains sarcodes and source should be free from TSE,Ecoli and salmonella so proof is required
7.	BM's Diphtherinum (Potency)	Deferred because The applied formulation contains poisonous Diphtherinum and safety profile of product is required
8.	BM's Etylicum (Potency)	Deferred for clarification of formulation and its rationality
9.	BM's Fabiana imbricata (Potency)	Deferred because The applied formulation contains sarcodes and source should be free from TSE,Ecoli and salmonella
10.	BM's Glandula suprarenalis (Potency)	Deferred because The applied formulation contains sarcodes and source should be free from TSE,Ecoli and salmonella need proof
11.	BM's Helix tosta (Potency)	Deferred because The applied formulation contains sarcodes and source should be free from TSE,Ecoli and salmonella need proof
12.	BM's Heloderma (Potency)	Deferred because The applied formulation contains poisonous Heloderma and safety profile of product is required.
13.	BM's Hippozaeninum (Potency)	Deferred because The applied formulation contains sarcodes and source should be free from TSE,Ecoli and salmonella need proof
14.	BM's Homarus (Potency)	Deferred because The applied formulation contains poisonous Homarus and safety profile of product is required
15.	BM's Hypophysis posterior (Potency)	Deferred because The applied formulation contains sarcodes and source should be free from TSE,Ecoli and salmonella need proof

S.No	Brand name	Decision
(1)	(2)	(3)
16.	BM's Lacerta agilis (Potency)	Deferred because The applied formulation contains poisonous Lacerta agilis green lizard and safety profile of product is required
17.	BM's Latrodectus katipo (Potency)	Deferred because The applied formulation contains poisonous Latrodectus katipo and safety profile of product is required
18.	BM's Latrodectus mactans (Potency)	Deferred because The applied formulation contains poisonous Latrodectus mactans and safety profile of product is required
19.	BM's Levico (Potency)	Deferred for clarification of formulation contain Only water
20.	BM's Oniscus asellus (Potency)	Deferred because The applied formulation contains poisonous Oniscus asellus and safety profile of product is required
21.	BM's Pulex irritans (Potency)	Deferred because The applied formulation contains poisonous Pulex irritans and safety profile of product is required
22.	BM's Scilla maritima (Potency)	Deferred because The applied formulation contains sarcodes and source should be free from TSE,Ecoli and salmonella
23.	BM's Scolopendra (Potency)	Deferred because The applied formulation contains poisonous Scolopendra and safety profile of product is required
24.	BM's Streptococcinum (Potency)	Deferred because The applied formulation contains sarcodes and source should be free from TSE,Ecoli and salmonella
25.	BM's Succinum (Potency)	Deferred for clarification of preparation of Succinum
26.	BM's Thallium metallicum (Potency)	Deferred because The applied formulation contains thallium and require stringent requirement of storage handling and preparation and safety profile of product is required
27.	BM's Toxicophis pugnax (Potency)	Deferred because The applied formulation contains poisinious Toxicophis pugnax and safety profile of product is required
M/s Haigher Pharma Pvt. Ltd., (E.NO: 01205) Plot No. 09, Pharma Square, 23-Km Raiwind Road, Lahore		
28.	Electral Sachet	EEC decided to defer the application for enlistment due to following reasons: Submit Rs. 3000/- as differential fee. The firm applid ORS formulation which is added in the list of common molecules. The firm applid similar formulation with brand name "HRH Plus Sachet"
29.	HRH Plus Sachet	EEC decided to defer the application for enlistment due to following reasons: The firm applid ORS formulation which is added in the list of common molecules. The firm applid similar formulation with brand name "Electral Sachet)
M/s MSG Nutraceuticals Plot # 34, S-1, RCCI, Industrial Estate Rawat, Islamabad		
30.	PRO-CHAIN SACHET :	Deferred with final opportunity to provide the required documents.
31.	Lactocell Sachet	Deferred with final opportunity to provide the required documents.
32.	Progot Sachet	Deferred with final opportunity to provide the required documents.
M/s Biozone International Plot No. 8, Bhengrail Road, Rawat, Islamabad		
33.	Biozone's Biobone Sachet	Deferred for the change of brand name.
34.	Biozone's Bone-S Sachet	Deferred for the change of brand name.
35.	Biozone's Myo-D Sachet	Deferred for the change of brand name.
36.	Oxford Sachet	Deferred for the change of brand name.
Filix Pharmaceuticals (Pvt) Ltd., Plot No. 4-A, Mian Road, R.C.C.I Rawat, Islamabad.		
37.	Pregnostol Sachets	EEC decided to defer the application for enlistment with final opportunity to fulfill the following deficiencies: <ul style="list-style-type: none">Form-3 is not signed stamped.Evidence of fee submission is required.Provide monograph of all ingredients.Undertakings regarding truthfulness of contents are required on notarized stamp paper duly signed

S.No	Brand name	Decision
(1)	(2)	(3)
38.	TestoMen Sachet	EEC decided to defer the application for enlistment with final opportunity to fulfill the following deficiencies: <ul style="list-style-type: none"> Form-3 is not signed stamped. Provide monograph of all ingredients. Undertakings regarding truthfulness of contents are required on notarized stamp paper duly signed
PDH Health Care, 42 Nicholson Road, Lahore		
39.	PDH Healthcare's Fizzy Cream	EEC decided to defer the application for enlistment with final opportunity to fulfill following deficiencies:- <ul style="list-style-type: none"> Brand name needs to be changed. The applied formulation has insignificant difference with Jointer Cream, need clarification. Provide undertaking regarding submission of stability data on company's letter head duly signed by owner of the firm.
M/S. Nutrifactor Laboratories (Pvt) Ltd Plot No 4-B, Value Addition City, Khurrianwala, Faisalabad		
40.	Xtragon Sachet	EEC decided to defer the application for enlistment and to give final opportunity for Provision of Glucomannan monograph.
Ms Asfar Health Care, 34-A, Punjab Small Industrial Area, Kasur		
41.	Asfar's Sherbet Sandal	EEC decided to defer the application to Provide undertakings regarding brand name resemblance and truthfulness of contents on notarized stamp paper duly signed by CEO/MD/owner of the firm.
42.	Asfar's Sherbet Bazoori	EEC decided to defer the application to Provide undertakings regarding brand name resemblance and truthfulness of contents on notarized stamp paper duly signed by CEO/MD/owner of the firm.
43.	Asfar's Colic-calm Drop	Deferred for the change of brand name
M/s. Blossom Laboratories (Pvt.) Ltd., 30-KM, Badian Road, ½ K.M Off Roda Bohgal Road, Lahore Cant (00181)		
44.	Blosmoton general tonic	EEC decided to defer the application for enlistment due to following reasons: Justification and Rationality of formulation as more than 20 active ingredients are used in formulation
45.	Ener-Vit Iron Tonic	EEC decided to defer the application for enlistment due to following reasons: The applied formulation contains controlled drug substance/precursor Coca Brand name needs to be changed
46.	Blossom's Nervolex Desponedent Drops	EEC decided to defer the application for enlistment due to following reasons: Brand name needs to be changed
47.	Blossom's Birthoff Capsule	EEC decided to defer the application for enlistment due to following reasons: Brand name needs to be changed
48.	Blossom's Perfect Height Drops	EEC decided to defer the application for enlistment due to following reasons: Brand name needs to be changed
49.	Blossom's Pain Shoot Tablets	EEC decided to defer the application for enlistment due to following reasons: Brand name needs to be changed
50.	Blossom's Gastocid Syrup	EEC decided to defer the application for enlistment due to following reasons: Brand name needs to be changed
51.	Blossom's Tempolex Syrup	EEC decided to defer the application for enlistment due to following reasons: Brand name needs to be changed
52.	Blossom's Heptolex Syrup	EEC decided to defer the application for enlistment due to following reasons: Brand name needs to be changed

S.No	Brand name	Decision
(1)	(2)	(3)
53.	Blossom's Mr Gastro Ulcer CAPSULE	EEC decided to defer the application for enlistment due to following reasons: Brand name needs to be changed
54.	Blossom's Ginza Lir Syrup	EEC decided to defer the application for enlistment due to following reasons: Brand name needs to be changed
55.	Blossom's Ginza Coff not Powder	EEC decided to defer the application for enlistment due to following reasons: Brand name needs to be changed
56.	Blossom's Ginza Diabe Non Tablets	EEC decided to defer the application for enlistment due to following reasons: Brand name needs to be changed
57.	Blossom's Ginza Artho lock Tablets	EEC decided to defer the application for enlistment due to following reasons: Brand name needs to be changed
58.	Blossom's Ginza Blood Filter Syrup	EEC decided to defer the application for enlistment due to following reasons: Brand name needs to be changed
59.	Blossom's Ginza Bumpbaby xSyrup	EEC decided to defer the application for enlistment due to following reasons: Brand name needs to be changed
60.	Blossom's Ginza Artho Lock Drops	EEC decided to defer the application for enlistment due to following reasons: Brand name needs to be changed
61.	Blossom's Ginza Artho Lock Syrup	EEC decided to defer the application for enlistment due to following reasons: Brand name needs to be changed
62.	Blossom's Ginza allegro nol powder	EEC decided to defer the application for enlistment due to following reasons: Brand name needs to be changed
63.	Blossom's Ginza Climb Height Tablets	EEC decided to defer the application for enlistment due to following reasons: Brand name needs to be changed
64.	Blossom's Smart Care Powder	EEC decided to defer the application for enlistment due to following reasons: Brand name needs to be changed
65.	Blossom's Hep-Heal Elixir	EEC decided to defer the application for enlistment due to following reasons: Brand name needs to be changed
66.	Blossom's Ginza Blood Mass Syrup	EEC decided to defer the application for enlistment due to following reasons: Brand name needs to be changed
67.	Blossom's Ginza Hepatic Syrup	EEC decided to defer the application for enlistment due to following reasons: Brand name needs to be changed
68.	Blossom's Ginza safe Bone Syrup	EEC decided to defer the application for enlistment due to following reasons: Brand name needs to be changed
69.	Blossom's Ginza Jointen syrup	EEC decided to defer the application for enlistment due to following reasons: Brand name needs to be changed
70.	Blossom's Ginza Kidnia Care Syrup	EEC decided to defer the application for enlistment due to following reasons: Brand name needs to be changed
M/s. Modherbs, Plot No. C-596, Sector 2, Ahsanabad, Scheme-33, Opp SITE, Super Highway, Karachi		
71.	Basopan Tablet	Deferred with final opportunity for submission of brand name and strength of extracts of the herbs instead of herbs
Paul Brooks Homoeo Labs, Karachi (E. No.0088) Plot No. A-69, S.I.T.E., Super Highway Phase-I, Karachi (Homoeopathy)		

S.No (1)	Brand name (2)	Decision (3)
72.	RELAXATIL CAPSULE	Deferred with final opportunity for provision of monograph of extract of Maitake Grifolafrondosa and Holy Basil Extract, Ocimum sanctum, Black Currant Extract, Ribes nigrum
M/s Cure Inn Phytoceuticals Pvt Ltd, Lahore (86)		
73.	Cure Inn's Z-Cal-D Tablet	Deferred with final opportunity for the provision of: <ul style="list-style-type: none"> • Monograph of coral calcium. • Change of brand name.
74.	Cure Inn's Fendi Syrup	Deferred with final opportunity for provision of monograph of honey and confirmation of herbal syrup section
75.	Cure Inn's Neurotip Tablet	Deferred for change of brand name
76.	Cure Inn's Glurex- P Tablet	Deferred with final opportunity for submission of evidence of fee submission and change of brand name
Pharmvevo Private Limited		
77.	E-Forte Soft-gel capsule	Deferred for the following deficiencies: <ul style="list-style-type: none"> ➤ Stability studies undertaking is unsigned/ unstamped. ➤ Band name and contents undertakings are not provided.
78.	E-Vit 600mg Soft-gel capsule	Deferred for the following deficiencies: <ul style="list-style-type: none"> ➤ Stability studies undertaking is unsigned/ unstamped. ➤ Band name and contents undertakings are not provided.
79.	E-Vit 400mg Soft-gel Capsule	Deferred for the following deficiencies: <ul style="list-style-type: none"> ➤ Stability studies undertaking is unsigned/ unstamped. ➤ Band name and contents undertakings are not provided.
M/s Classic Nutraceutical Labs, Plot No.89, 15km, Hangu Road, Kohat-Pakistan (Veterinary)		
80.	Classic's Temp Cure Syrup	Deferred with final opportunity for submission of deficiency of Temp Cure Syrup
M/s Nutrabiobiotics, Nutritional Life Science (E. No. 003) Plot No. 32-33, Small Industrial Estate, Kohat Road, Peshawar		
81.	GERI-V TABLET	EEC decided to defer the product with the final opportunity to change the brand name.
82.	ENZOWELL CAPSULE	Deferred with final opportunity for provision of strength of ingredients in their extract form
83.	CALCIUM D3 SYRUP	Deferred with final opportunity for change of brand name
84.	NUTRABIOTICS VITAMINS & MINERALS SYRUP	Deferred with final opportunity for change of brand name
85.	NEUROTOP SYRUP	EEC decided to defer the product with the final opportunity to change the brand name.
86.	ZOPAIR CAPSULE	Deferred for the clarification of two formulations in one pack
M/s Thermion Pharmaceuticals & Chemicals (Pvt.) Ltd., 147/5, Block B, Labour Colony, Off Defense Road, Lahore agent of M/s Jinan GSY Biotechnology Co. Ltd., 296 Km, 700 Meters, 220 State Highway, Xiaoli Town, Changqing District Jinan City, Shangdong Province, China (E. No. 01095)		
87.	Chick Shine Oral Solution	Deferred since Formulaiton contains Silymarin which is included in the list of common molecules.
M/s Bio-Oxime Pharmaceuticals, Plot # 31,32 Millat Garment City Dry Port Road, Faisalabad agent of M/s Tanin Sevnica D.D, Hermanova Cesta 1, 8290 Sevnica, Slovenia (E. No. 00987)		
88.	Farmatan Liquid	Deferred with final opportunity for the submission of following deficiencies: Real time and accelerated Stability Studies data of atleast three batches is not provided as per the prescribed conditions of Zone IV A.
M/s. Dr. Salim Ahmed & Co (Homoeopathic), 310 Hashoo Centre, Abdullah Haroon Road, Karachi-Pakistan M/s Dr. Reckeweg & Co. GmbH, Berliner Ring 32, 64625 Bensheim, GERMANY (E. No. 00247)		
89.	Dr. Reckeweg R22 Najasthen	Deferred for further deliberation for safety profile of Naga, Lachesis and poisonous snake preparation.
M/s. McPharm International (Pvt) Ltd., 219-A, Lalazar Commercial Market, Raiwind Road, Lahore agent of M/s. Sanli Ilac A.S A.O.S.B 10046 Sokak No. 6 eigli Izmir, Turkey (E. No. 00813)		
90.	Sanli Capsicum Ointment	Deferred with final opportunity for the submission of following deficiencies:

S.No	Brand name	Decision
(1)	(2)	(3)
		Real time stability studies data provided is not according to the prescribed conditions of Zone IV A. Methyl Salicylate is included in the list of common molecules. Current status of GMP Compliance of principal manufacturer. Original attested copy of Free sale certificate issued by the concern regulatory body in the country of Origin is not provided.
91.	Sanli Menthol Ointment	Deferred with final opportunity for the submission of following deficiencies: Real time stability studies data provided is not according to the prescribed conditions of Zone IV A. Methyl Salicylate is included in the list of common molecules. Current status of GMP Compliance of principal manufacturer. Original attested copy of Free sale certificate issued by the concern regulatory body in the country of Origin is not provided.
92.	Kataljin Ointment	Deferred with final opportunity for the submission of following deficiencies: Different strengths of camphor are mentioned on different documents. Real time and accelerated Stability Studies data of atleast three batches is not provided as per the prescribed conditions of Zone IV A. Current status of GMP Compliance of principal manufacturer. Original attested copy of Free sale certificate issued by the concern regulatory body in the country of Origin is not provided.
M/s ZS Biotech Animal Health Company, 22-A, Hadayat Ullah Block Mustafa Town Wahdat Road, Lahore agent of M/s Biochem Zusatzstoffe Handels – und Produktionsges, mbH, Brageler Forst 13, D-49393 Lohne, Germany (E. No. 00883)		
93.	Fertility Pack Cattle	Deferred with final opportunity for the provision of following documents: Real time and accelerated Stability Studies data of atleast three batches is not provided as per the prescribed conditions of Zone IV A. Current status of GMP Compliance of principal manufacturer.
94.	Energy-Top	Deferred with final opportunity for the provision of following documents: Real time and accelerated Stability Studies data of atleast three batches is not provided as per the prescribed conditions of Zone IV A. Current status of GMP Compliance of principal manufacturer.
95.	ProB.I.O -Sacc 10%	Deferred with final opportunity for the provision of following documents: Real time and accelerated Stability Studies data of atleast three batches is not provided as per the prescribed conditions of Zone IV A. Current status of GMP Compliance of principal manufacturer. Testing specification of saccharomyces cerevisiae is required.
96.	RumiPro Top	Deferred with final opportunity for the provision of following documents: Real time and accelerated Stability Studies data of atleast three batches is not provided as per the prescribed conditions of Zone IV A. Current status of GMP Compliance of principal manufacturer. Clarification regarding role of bentonite and sepiolite as health products is required.
97.	4 Immunity	Deferred with final opportunity for the provision of following documents: Real time and accelerated Stability Studies data of atleast three batches is not provided as per the prescribed conditions of Zone IV A. Current status of GMP Compliance of principal manufacturer. Justification of use of vitamin K3 is required since former has been banned for intended use owing to side effects.
98.	Bimulac Extra	Deferred with final opportunity for the provision of following documents: Real time and accelerated Stability Studies data of atleast three batches is not provided as per the prescribed conditions of Zone IV A. Current status of GMP Compliance of principal manufacturer. Testing specification of probiotics is required.

S.No	Brand name	Decision
(1)	(2)	(3)
99.	Calf Protector	Deferred with final opportunity for the provision of following documents: Real time and accelerated Stability Studies data of atleast three batches is not provided as per the prescribed conditions of Zone IV A. Current status of GMP Compliance of principal manufacturer. Testing specification of probiotics is required. Pack size not provided.
100.	Keto Gel	Deferred with final opportunity for the provision of following documents: Real time and accelerated Stability Studies data of atleast three batches is not provided as per the prescribed conditions of Zone IV A. Current status of GMP Compliance of principal manufacturer.
101.	Cal Gel	Deferred with final opportunity for the provision of following documents: Real time and accelerated Stability Studies data of atleast three batches is not provided as per the prescribed conditions of Zone IV A. Current status of GMP Compliance of principal manufacturer.
M/s ZS Biotech Animal Health Company, located at the address 50-C Madina Block Awan Town, Multan Road, Lahore agent of M/s Nor Feed, Angers Technopole 3 rue Amedeo Avogadro 49070, Beaucouze, France (E. No. 00910)		
102.	Norponin ® XO2	Deferred with final opportunity for the provision of following documents: Real time and accelerated Stability Studies data of atleast three (03) batches is not provided as per the prescribed conditions of Zone IV A.
M/s ZS Biotech, 50-C Madina Block Awan Town Multan Road, Lahore-Pakistan agent of M/s Herbavita BVBA, Avelgemstraat 17, 9690 Kluisbereggen, Belgium (E. No. 00467)		
103.	AviForm Yeast +	Deferred with final opportunity for the provision of following documents: Real time and accelerated Stability Studies data of atleast three (03) batches is not provided as per the prescribed conditions of Zone IV A. Current status of GMP Compliance of principal manufacturer. Testing specification of probiotics is required.
104.	Herbacid-Cow	Deferred with final opportunity for the provision of following documents: Real time and accelerated Stability Studies data of atleast three (03) batches is not provided as per the prescribed conditions of Zone IV A. Current status of GMP Compliance of principal manufacturer.
105.	Vitachor C-Plus	Deferred with final opportunity for the provision of following documents: Real time and accelerated Stability Studies data of atleast three (03) batches is not provided as per the prescribed conditions of Zone IV A. Current status of GMP Compliance of principal manufacturer. Strength of passiflora incarnata is required..
M/s ZS Biotech, 50-C Madina Block Awan Town Multan Road, Lahore-Pakistan agent of M/s Beijing Strowin Biology Science and Technology Co., Ltd., Rm. 1411, 14th floor of No.2 building, 1st Place, Shangdi 10th Road, Haidian District, Beijin. [(Site: No.5 Chenma Road), 1000m to the East Jianggezhuang village, Mulin town, Shunyi District, Beijing] (Veterinary) (E. No. 00484)		
106.	Strophase 80	Deferred with final opportunity for the provision of following deficiencies: Provided copy of Free sale certificate is issued by Beiging Feed Industry Association which is not regulatory body in the country of origin. Current status of GMP Compliance of principal manufacturer. Clarification required with respect to product formulation and strength, whether its Nutraceutical product or not.
107.	Strophase 85	Deferred with final opportunity for the provision of following deficiencies:

S.No (1)	Brand name (2)	Decision (3)
		<p>Provided copy of Free sale certificate is issued by Beiging Feed Industry Association which is not regulatory body in the country of origin.</p> <p>Current status of GMP Compliance of principal manufacturer.</p> <p>Clarification required with respect to product formulation and strength, whether its Nutraceutical product or not.</p>
M/s Techno Care, located at the address 8-B, 1st floor, United Center, Shamsabad, Murree Road, Rawalpindi-Pakistan agent of M/s Shijiazhuang Zdhf Stock-Raising Co. Ltd., No.1, Yinhai Road, New Industrial Area, Weixian, country, Xingtai City, Hebei Province China (E. No. 00691)		
108.	Immune Care	Deferred with final opportunity for provision of following deficiencies: Free sale certificate does not depict that the said product is freely available in the country of Origin.
109.	Respo Care Plus	Deferred with final opportunity for provision of following deficiencies: Free sale certificate does not depict that the said product is freely available in the country of Origin.
110.	Vita Force S	Deferred with final opportunity for provision of following deficiencies: Free sale certificate does not depict that the said product is freely available in the country of Origin.
M/s Techno Care, located at the address 8-B, 1st floor, United Center, Shamsabad, Murree Road, Rawalpindi-Pakistan agent of M/s Hebei New Century Pharmaceutical Co., Ltd., No.189, Taihang Street, HI-Tech Zone SHI Jiazhuang City, China (E.No. 00690)		
111.	E-Sol Care 10%	Deferred with final opportunity for provision of following deficiencies: Free sale certificate does not depict that the said product is freely available in the country of Origin.
112.	MyCo Cid	Deferred with final opportunity for provision of following deficiencies: Free sale certificate does not depict that the said product is freely available in the country of Origin.
M/s. Titlis Pharma, located at the address 528-A, Sundar Industrial Estate, Raiwind Road, Lahore agent of M/s. The Menthos Company Limited, 1 Redwood Avenue, Peel Park Campus, East Kilbride G74 5PE, United Kingdom (E. No. 00810)		
113.	Deep Heat Max Strength Cream	Deferred as the The product formulation contains Methyl salicylate which is included in the list of common molecules.
M/s Vet Pharma Trading Company, New Street Market, Near Regent Cinema, GT Road, Gujranwala-Pakistan agent of M/s Genebiotech Co., Ltd., 166 Sinwonsa-ro, Gyeryong-myeon, Gongju-si, Chungcheongnam-do 32619, Korea (Veterinary) (E. No. 00619)		
114.	DaOne Tocoseal	<p>Deferred with final opportunity for provision of following documents:</p> <ul style="list-style-type: none"> • Confirmation of receipt of application. • Format of provided copy of Free Sale certificate and name of issuing authority is different on all three (03) submitted applications from same country of origin.
115.	DaOne ADEK	<p>Deferred with final opportunity for provision of following documents:</p> <ul style="list-style-type: none"> • Confirmation of receipt of application. • Format of provided copy of Free Sale certificate and name of issuing authority is different on all three (03) submitted applications from same country of origin. • Justification of use of vitamin K3 is required since former has been banned for intended use owing to side effects.
116.	Livermarin Solution	<p>Deferred with final opportunity for provision of following documents:</p> <ul style="list-style-type: none"> • Confirmation of receipt of application. • Format of provided copy of Free Sale certificate and name of issuing authority is different on all three (03) submitted applications from same country of origin. • Clarification is required as milk thistle extract is not same as silymarin.
M/s Diversified Marketing Group (DMG), House # 245, Ground Floor, Saidpur Road, Scheme # 1, Rawalpindi agent of M/s Norel S.A., Pol.Ind.de Valls, Ctra. Pla Santa Maria, 271-273 43800. Valls (Tarragona), Spain (E. No. 00989)		

S.No	Brand name	Decision
(1)	(2)	(3)
117.	Glymet Fe 19%	Deferred with final opportunity for provision of Real time and accelerated Stability Studies data of atleast three (03) batches is not provided as per the prescribed conditions of Zone IV A.
118.	Glymet Zn 22%	Deferred with final opportunity for provision of Real time and accelerated Stability Studies data of atleast three (03) batches is not provided as per the prescribed conditions of Zone IV A.
119.	Glymet Mn 20%	Deferred with final opportunity for provision of Real time and accelerated Stability Studies data of atleast three (03) batches is not provided as per the prescribed conditions of Zone IV A.
120.	Glymet Cu 24%	Deferred with final opportunity for provision of Real time and accelerated Stability Studies data of atleast three (03) batches is not provided as per the prescribed conditions of Zone IV A.
121.	Glymet Mix Poultry	Deferred with final opportunity for provision of Real time and accelerated Stability Studies data of atleast three (03) batches is not provided as per the prescribed conditions of Zone IV A.
122.	Toxifree	Deferred with final opportunity for provision of Real time and accelerated Stability Studies data of atleast three (03) batches is not provided as per the prescribed conditions of Zone IV A.
M/s Orient Traders International, CM-10, Block-A, Kazimabad, Model Colony, Karachi-Pakistan agent of M/s CID Lines NV, Waterpoorstraat 2 8900 Ieper, Belgium (Veterinary) (E. No. 00614)		
123.	Kenovit E	Deferred with final opportunity for the provision of following documents: Real time and accelerated Stability Studies data of atleast three (03) batches is not provided as per the prescribed conditions of Zone IV A. Current status of GMP Compliance of principal manufacturer.
M/s Organs Pharma (Pvt) Ltd., office No.2, 2nd floor Plot No.50-D, Khayaban-e-Itehad, Muslim Commercial Area Phase VI, Karachi-Pakistan agent of M/s ABH Nature's Products, Inc. dba ABH Pharma Inc. 131 Heartland Boulevard Edgewood, NY 11717, USA (E.No. 00582)		
124.	Glitex Plus Tablet	Deferred with final opportunity for provision of following documents: <ul style="list-style-type: none"> • Application form 5 is not signed and stamped. • Testing specification, monographs, COAs of raw materials and finished product are not provided. • Undertaking on notarized stamp paper not provided. • Stability studies data not provided. • Current status of GMP Compliance of principal manufacturer. • Original attested copy of Free sale certificate issued by the concern regulatory body in the country of Origin is not provided
M/s Rana Shaukat Ali, P-130/6, St-06, Fatehabad-East, Satiana Road, Faisalabad agent of M/s Shanghai Niu Beile Bio-tech Co., Ltd. No.2, Lane 1200, Xiechun Road, Huangdu Town, Jiading (E. No. 0098)		
125.	Angi-Guard Softgel	Deferred with final opportunity for provision of following documents: <ul style="list-style-type: none"> • Application form 5 as per prescribed format under SRO 412(I)/2014. • Real time and accelerated Stability Studies data of atleast three (03) batches is not provided as per the prescribed conditions of Zone IV A. • Current status of GMP Compliance of principal manufacturer. • Original attested copy of Free sale certificate issued by the concern regulatory body in the country of Origin is not provided.
126.	HSN Softgel	Deferred with final opportunity for provision of following documents: <ul style="list-style-type: none"> • Application form 5 as per prescribed format under SRO 412(I)/2014. • Real time and accelerated Stability Studies data of atleast three (03) batches is not provided as per the prescribed conditions of Zone IV A. • Current status of GMP Compliance of principal manufacturer. • Original attested copy of Free sale certificate issued by the concern regulatory body in the country of Origin is not provided.
127.	Daily One Softgel	Deferred with final opportunity for provision of following documents: <ul style="list-style-type: none"> • Application form 5 as per prescribed format under SRO 412(I)/2014. • Real time and accelerated Stability Studies data of atleast three (03) batches is not provided as per the prescribed conditions of Zone IV A. • Current status of GMP Compliance of principal manufacturer. • Original attested copy of Free sale certificate issued by the concern regulatory body in the country of Origin is not provided.

S.No (1)	Brand name (2)	Decision (3)
128.	Bone-Z Softgel	Deferred with final opportunity for provision of following documents: <ul style="list-style-type: none"> • Application form 5 as per prescribed format under SRO 412(I)/2014. • Real time and accelerated Stability Studies data of atleast three (03) batches is not provided as per the prescribed conditions of Zone IV A. • Current status of GMP Compliance of principal manufacturer. • Original attested copy of Free sale certificate issued by the concern regulatory body in the country of Origin is not provided.
129.	Calcium Plus Softgel	Deferred with final opportunity for provision of following documents: <ul style="list-style-type: none"> • Application form 5 as per prescribed format under SRO 412(I)/2014. • Real time and accelerated Stability Studies data of atleast three (03) batches is not provided as per the prescribed conditions of Zone IV A. • Current status of GMP Compliance of principal manufacturer. • Original attested copy of Free sale certificate issued by the concern regulatory body in the country of Origin is not provided.
130.	Liferon Softgel	Deferred with final opportunity for provision of following documents: <ul style="list-style-type: none"> • Application form 5 as per prescribed format under SRO 412(I)/2014. • Real time and accelerated Stability Studies data of atleast three (03) batches is not provided as per the prescribed conditions of Zone IV A. • Current status of GMP Compliance of principal manufacturer. • Original attested copy of Free sale certificate issued by the concern regulatory body in the country of Origin is not provided. • The formulation include Slymarin, which is included in the list of common molecule.
131.	WEGO Softgel	Deferred with final opportunity for provision of following documents: <ul style="list-style-type: none"> • Application form 5 as per prescribed format under SRO 412(I)/2014. • Real time and accelerated Stability Studies data of atleast three (03) batches is not provided as per the prescribed conditions of Zone IV A. • Current status of GMP Compliance of principal manufacturer. • Original attested copy of Free sale certificate issued by the concern regulatory body in the country of Origin is not provided.
132.	Bio-Chill Softgel	Deferred with final opportunity for provision of following documents: <ul style="list-style-type: none"> • Application form 5 as per prescribed format under SRO 412(I)/2014. • Real time and accelerated Stability Studies data of atleast three (03) batches is not provided as per the prescribed conditions of Zone IV A. • Current status of GMP Compliance of principal manufacturer. • Original attested copy of Free sale certificate issued by the concern regulatory body in the country of Origin is not provided.
M/s Mian Traders, Khan Piyara, Post Office Mahlowala, Guranwala, District Gujranwala, Punjab-Pakistan agent of M/s APA United Nano Technology Co., Ltd., Lot C2-4, Vinh Loc 2 Industrial Zone, VL3 Street, Vio La Hamlet, Long Hiep Commune, Ben Luc District, Long An Province, Vietnam (Veterinary) (E. No. 00609)		
133.	Hydra Plus	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> Testing specification, monographs, COAs of raw materials and finished product are not provided. Testing parameters are not defined in the provided stability studies data of the applied product. Current status of GMP Compliance of principal manufacturer. Original attested copy of Free sale certificate issued by the concern regulatory body in the country of Origin is not provided.
134.	ADECK Gold	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> Testing specification, monographs, COAs of raw materials and finished product are not provided. Testing parameters are not defined in the provided stability studies data of the applied product. Current status of GMP Compliance of principal manufacturer. Original attested copy of Free sale certificate issued by the concern regulatory body in the country of Origin is not provided. Justification of use of vitamin K3 is required since former has been banned for intended use owing to side effects.

S.No	Brand name	Decision
(1)	(2)	(3)
135.	Ultra-C Plus	Deferred with final opportunity for the provision of following documents: Testing specification, monographs, COAs of raw materials and finished product are not provided. Testing parameters are not defined in the provided stability studies data of the applied product. Current status of GMP Compliance of principal manufacturer. Original attested copy of Free sale certificate issued by the concern regulatory body in the country of Origin is not provided.
136.	Lyso-Gold Plus	Deferred with final opportunity for the provision of following documents: Testing specification, monographs, COAs of raw materials and finished product are not provided. Testing parameters are not defined in the provided stability studies data of the applied product. Current status of GMP Compliance of principal manufacturer. Original attested copy of Free sale certificate issued by the concern regulatory body in the country of Origin is not provided.
137.	Aminovit Gold Oral Solution	Deferred with final opportunity for the provision of following documents: Testing specification, monographs, COAs of raw materials and finished product are not provided. Testing parameters are not defined in the provided stability studies data of the applied product. Current status of GMP Compliance of principal manufacturer. Original attested copy of Free sale certificate issued by the concern regulatory body in the country of Origin is not provided.
M/s Ghazi Brothers, Ghazi House, D-35, KDA Scheme #1, Miran Muhammad Shah Road, Karachi-75350-Pakistan agent of M/s Angel Yeast Co., Ltd., 168 Chengdong Avenue, Yichang, Hubei 443003, China (Veterinary) (E. No.00516)		
138.	Fubon Active Feed Dry Yeast	Deferred with final opportunity for the provision of following documents: GMP Certificate is issued by SGS, which is not a regulatory body in the country of origin. Audit report is issued by SAI Global, which is not a regulatory body in the country of Origin. Free Sale certificate is issued by The Feed Industrial Office which is not a regulatory body in the country of origin. Whereas, according to provided copy of Feed Production License/Manufacturing authorization the name of relevant regulatory body is Agriculture department of Hubei province, China. Stability Studies data is not as per prescribed conditions of Zone IV A.
139.	Fubon Mycotoxin Binder	Deferred with final opportunity for the provision of following documents: GMP Certificate is issued by SGS, which is not a regulatory body in the country of origin. Audit report is issued by SAI Global, which is not a regulatory body in the country of Origin. Free Sale certificate is issued by The Feed Industrial Office which is not a regulatory body in the country of origin. Whereas, according to provided copy of Feed Production License/Manufacturing authorization the name of relevant regulatory body is Agriculture department of Hubei province, China. Stability Studies data is not as per prescribed conditions of Zone IV A.
M/s Ghazi Brothers, Ghazi House, D-35, KDA Scheme # 1, Miran Muhammad Shah Road, Karachi-75350-Pakistan agent of M/s Anpario, Unit 5 Manton Wood Enterprise Park, Workso, Nottinghamshire, S80 2RS, UK. (Veterinary) (E. No. 00474)		
140.	Orego –Stim Liquid	Deferred with final opportunity for the provision of following documents: Stability Studies data is not as per prescribed conditions of Zone IV A.

S.No	Brand name	Decision
(1)	(2)	(3)
		GMP certificate and inspection report issued by concern regulatory body are not provided.
141.	Orego-Stim Powder	Deferred with final opportunity for the provision of following documents: Stability Studies data is not as per prescribed conditions of Zone IV A. GMP certificate and inspection report issued by concern regulatory body are not provided.
142.	Fusion OS	Deferred with final opportunity for the provision of following documents: Stability Studies data is not as per prescribed conditions of Zone IV A. GMP certificate and inspection report issued by concern regulatory body are not provided.
M/s Ghazi Brothers, located at the address Ghazi House, D-35, KDA Scheme #1, Miran Muhammad Shah Road, Karachi-75350-Pakistan agent of M/s Shanghai Menon Animal Nutrition Technology Co., Ltd., No.151, Lihong Rd, Jiading District, Shanghai, China (E. No. 00663)		
143.	Menogen	Deferred with final opportunity for the provision of following documents: GMP Certificate and inspection report are issued by HSL Certification Service, which is not a regulatory body in the country of origin. Manufacturing License and Free Sale certificate are issued by Shanghai Feed Industry Office. Clarification is required w.r.t its status as a concern government regulatory body. Stability Studies data is not as per prescribed conditions of Zone IV A. Use of urea under SRO is required.
144.	Menoso 30	Deferred with final opportunity for the provision of following documents: GMP Certificate and inspection report are issued by HSL Certification Service, which is not a regulatory body in the country of origin. Manufacturing License and Free Sale certificate are issued by Shanghai Feed Industry Office. Clarification is required w.r.t its status as a concern government regulatory body. Stability Studies data is not as per prescribed conditions of Zone IV A.
145.	Menacid 300	Deferred with final opportunity for the provision of following documents: GMP Certificate and inspection report are issued by HSL Certification Service, which is not a regulatory body in the country of origin. Manufacturing License and Free Sale certificate are issued by Shanghai Feed Industry Office. Clarification is required w.r.t its status as a concern government regulatory body. Stability Studies data is not as per prescribed conditions of Zone IV A.
146.	Menoco	Deferred with final opportunity for the provision of following documents: GMP Certificate and inspection report are issued by HSL Certification Service, which is not a regulatory body in the country of origin. Manufacturing License and Free Sale certificate are issued by Shanghai Feed Industry Office. Clarification is required w.r.t its status as a concern government regulatory body. Stability Studies data is not as per prescribed conditions of Zone IV A.
147.	Menomet	Deferred with final opportunity for the provision of following documents: GMP Certificate and inspection report are issued by HSL Certification Service, which is not a regulatory body in the country of origin.

S.No	Brand name	Decision
(1)	(2)	(3)
		Manufacturing License and Free Sale certificate are issued by Shanghai Feed Industry Office. Clarification is required w.r.t its status as a concern government regulatory body. Stability Studies data is not as per prescribed conditions of Zone IV A.
M/s Ghazi Brothers, located at the address Ghazi House, D-35, KDA Scheme #1, Miran Muhammad Shah Road, Karachi-75350-Pakistan agent of M/s Easy Bio Inc. 222, Gunsu 1-gil, Jiksan-eup, Seobuk-gu, Cheonan-si, Chungcheongnam-do, Korea (Veterinary) (E. No. 00719)		
148.	Endo-Power Beta	Deferred with final opporuting for the provision of following documents: GMP Certificate is issued by SGS, which is not a regulatory body in the country of origin. Audit report is issued by Lloyd's Register (LRQA), which is not a regulatory body in the country of Origin. Stability Studies data is not as per prescribed conditions of Zone IV A. α – galactosidase is an enzyme being used in Fabry's disease (a rare disease). In this regard, use of α – galactosidase as veterinary food supplement is required.
M/s Ghazi Brothers, located at the address Ghazi House, D-35, KDA Scheme #1, Miran Muhammad Shah Road, Karachi-75350-Pakistan agent of M/s Cheil Bio Co. Ltd., 131, Sandan-ro 83 beon-gil, Danwon-gu, Ansan-si, Gyeonggi-Do, Korea (E. No. 00660)		
149.	Multisol-G	Deferred with final opportunity for the provision of following documents: Current status of GMP Compliance of principal manufacturer. Type of vitamin K being used in formulation is required.
M/s Zuram Brothers, 522-Hamza Block, Street No. 6, Green View Colony, Faisalabad agent of M/s Nutech Biosciences, Inc. 537 Fitch Street, Oneida, New York 13421, USA. (Veterinary) (E. No. 00511)		
150.	Mycobond	Deferred for clarification and justification of formulation and role of clay as nutraceutical health product under SRO 412
M/s Zuram Brothers, 522-Hamza Block, Street No.6, Green View Colony, Faisalabad agent of M/s DAEHO Co., Ltd., #24, Jeongmunsongsan – ro 241 beon-gil, Yanggam-myeon, Hwaseong-si, Gyeonggi-do, Korea (E. No. 00438)		
151.	Keywest	Deferred with final opportunity for the provision of following documents: Clarification is required w.r.t. role of Silicon Dioxide in the formulation. Provided label spicemen is not appropriate. Stability Studies data is not provided as per prescribed conditions of Zone IV A.
M/s Asra Derm, Office No.22-24, 3rd floor, Al-Hafeez Tower, M.M Alam Road, Gulberg-III, Lahore agent of M/s Biota Lab, Emek Mah, Sirat Yohu Cod No. 09 Sancabtepe, Istanbul, Turkey (E. No.00451)		
152.	Nutraxin Big Energy Tablet	Deferred with final opportunity for provision of following documents: <ul style="list-style-type: none"> Applied brand name is not appropriate. Formulation contains caffeine, which is included in the list of common molecule. Stability Studies data provided is not as per the conditions of Zone IV A. Current status of GMP Compliance of principal manufacturer. Original attested copy of Free sale certificate issued by the concern regulatory body in the country of Origin is not provided.
M/s Gee Vet International, office. 11/12, first floor, Naz Medicine Market Namak Mandi, Peshawar-Pakistan agent of M/s Inner Mongolia Huatain Pharmaceutical Co. Ltd., Economic Development Zone, Yuanbaoshan District ChiFeng city, Inner Mongolia, P.R. China (Veterinary) (E. No. 00602)		
153.	Broncho Chick Double Strength	Deferred with final opportunity for provision of following documents: <ul style="list-style-type: none"> The brand name mentioned on provided copy of stability studies data, Free sale certificate and CoA is different from the applied brand name. Real time stability studies data is not as per prescribed conditions of Zone IV A. Free sale certificate is issued by Veterinary Bureau of Inner Mongolia, where as according to provided copy of manufacturing license the

S.No	Brand name	Decision
(1)	(2)	(3)
		<p>name of concern regulatory body is Ministry of Agriculture of P.R. China.</p> <ul style="list-style-type: none"> Current status of GMP Compliance of principal manufacturer.
154.	Neo-Acid Oral Solution	<p>Deferred with final opportunity for provision of following documents:</p> <ul style="list-style-type: none"> The brand name mentioned on provided copy of stability studies data, Free sale certificate and CoA is different from the applied brand name. Real time stability studies data is not as per prescribed conditions of Zone IV A. Free sale certificate is issued by Veterinary Bureau of Inner Mongolia, where as according to provided copy of manufacturing license the name of concern regulatory body is Ministry of Agriculture of P.R. China. Current status of GMP Compliance of principal manufacturer.
155.	Liver Gold 5L	<p>Deferred with final opportunity for provision of following documents:</p> <ul style="list-style-type: none"> The brand name mentioned on provided copy of stability studies data, Free sale certificate and CoA is different from the applied brand name. Real time stability studies data is not as per prescribed conditions of Zone IV A. Free sale certificate is issued by Veterinary Bureau of Inner Mongolia, where as according to provided copy of manufacturing license the name of concern regulatory body is Ministry of Agriculture of P.R. China. Current status of GMP Compliance of principal manufacturer.
156.	Vita Cool	<p>Deferred with final opportunity for provision of following documents:</p> <ul style="list-style-type: none"> The brand name mentioned on provided copy of stability studies data, Free sale certificate and CoA is different from the applied brand name. Real time stability studies data is not as per prescribed conditions of Zone IV A. Free sale certificate is issued by Veterinary Bureau of Inner Mongolia, where as according to provided copy of manufacturing license the name of concern regulatory body is Ministry of Agriculture of P.R. China. Current status of GMP Compliance of principal manufacturer.
157.	Vita E Cell 20%	<p>Deferred with final opportunity for provision of following documents:</p> <ul style="list-style-type: none"> The brand name mentioned on provided copy of stability studies data, Free sale certificate and CoA is different from the applied brand name. Real time stability studies data is not as per prescribed conditions of Zone IV A. Free sale certificate is issued by Veterinary Bureau of Inner Mongolia, where as according to provided copy of manufacturing license the name of concern regulatory body is Ministry of Agriculture of P.R. China. Current status of GMP Compliance of principal manufacturer.
158.	Multi Forte ADEK	<p>Deferred with final opportunity for provision of following documents:</p> <ul style="list-style-type: none"> The brand name mentioned on provided copy of stability studies data, Free sale certificate and CoA is different from the applied brand name. Real time stability studies data is not as per prescribed conditions of Zone IV A. Free sale certificate is issued by Veterinary Bureau of Inner Mongolia, where as according to provided copy of manufacturing license the name of concern regulatory body is Ministry of Agriculture of P.R. China. Current status of GMP Compliance of principal manufacturer.
159.	Vita E Cell 15%	<p>Deferred with final opportunity for provision of following documents:</p>

S.No (1)	Brand name (2)	Decision (3)
		<ul style="list-style-type: none"> The brand name mentioned on provided copy of stability studies data, Free sale certificate and CoA is different from the applied brand name. Real time stability studies data is not as per prescribed conditions of Zone IV A. Free sale certificate is issued by Veterinary Bureau of Inner Mongolia, where as according to provided copy of manufacturing license the name of concern regulatory body is Ministry of Agriculture of P.R. China. Current status of GMP Compliance of principal manufacturer.
160.	Liver Gold	<p>Deferred with final opportunity for provision of following documents:</p> <ul style="list-style-type: none"> The brand name mentioned on provided copy of stability studies data, Free sale certificate and CoA is different from the applied brand name. Real time stability studies data is not as per prescribed conditions of Zone IV A. Free sale certificate is issued by Veterinary Bureau of Inner Mongolia, where as according to provided copy of manufacturing license the name of concern regulatory body is Ministry of Agriculture of P.R. China. Current status of GMP Compliance of principal manufacturer.
161.	Multi-Vet	<p>Deferred with final opportunity for provision of following documents:</p> <ul style="list-style-type: none"> The brand name mentioned on provided copy of stability studies data, Free sale certificate and CoA is different from the applied brand name. Real time stability studies data is not as per prescribed conditions of Zone IV A. Free sale certificate is issued by Veterinary Bureau of Inner Mongolia, where as according to provided copy of manufacturing license the name of concern regulatory body is Ministry of Agriculture of P.R. China. Current status of GMP Compliance of principal manufacturer.
162.	Vitamix (1000ml Oral Liquid)	<p>Deferred with final opportunity for provision of following documents:</p> <ul style="list-style-type: none"> The brand name mentioned on provided copy of stability studies data, Free sale certificate and CoA is different from the applied brand name. Real time stability studies data is not as per prescribed conditions of Zone IV A. Free sale certificate is issued by Veterinary Bureau of Inner Mongolia, where as according to provided copy of manufacturing license the name of concern regulatory body is Ministry of Agriculture of P.R. China. Current status of GMP Compliance of principal manufacturer.
163.	Electro Chick Powder	<p>Deferred with final opportunity for provision of following documents:</p> <ul style="list-style-type: none"> The brand name mentioned on provided copy of stability studies data, Free sale certificate and CoA is different from the applied brand name. Real time stability studies data is not as per prescribed conditions of Zone IV A. Free sale certificate is issued by Veterinary Bureau of Inner Mongolia, where as according to provided copy of manufacturing license the name of concern regulatory body is Ministry of Agriculture of P.R. China. Current status of GMP Compliance of principal manufacturer.
M/s Fartal Pharmaceuticals, Plot No.9, Street No.1, Model Colony, Karachi agent of M/s Laboratorios Microsules Uruguay S.A. (E. No. 00290)		
164.	Potenmic	<p>Deferred with final opportunity for provision of following documents:</p> <ul style="list-style-type: none"> Free sale certificate not provided. GMP certificate not provided. Stability studies data not provided as per prescribed conditions of Zone IV A.

S.No (1)	Brand name (2)	Decision (3)
		<ul style="list-style-type: none"> CoAs of raw material and finished products not provided. Glucose is added in common molecules list.
M/s Genetics Healthcare, located at the address 537-A, Sunder Industrial Estate, Lahore-Pakistan agent of M/s Zhejiang Autokang Pharmaceutical Group, Co. Ltd Dingye Xinaun, Wucheng District, Jinhua, Zhejiang, P.R. China (E. No. 00659)		
165.	Remore Tablets	<p>Deferred with final opportunity for the provision of following documents: The formulation contains N-acetylcysteine which is included in the list of Common molecules. Free sale certificate is issued by China chamber of commerce for import and export of medicines and health products, which is not a concern regulatory body. Further the said document does not depict the free availability of the applied product in the country of origin.</p>
166.	Keplin 15mg Tablet	<p>Deferred with final opportunity for the provision of following documents: Free sale certificate is issued by China chamber of commerce for import and export of medicines and health products, which is not a concern regulatory body. Further the said document does not depict the free availability of the applied product in the country of origin.</p>
167.	Keplin 7.5mg Tablet	<p>Deferred with final opportunity for the provision of following documents: Free sale certificate is issued by China chamber of commerce for import and export of medicines and health products, which is not a concern regulatory body. Further the said document does not depict the free availability of the applied product in the country of origin.</p>
168.	Neurogen Tablet	<p>Deferred with final opportunity for the provision of following documents: Free sale certificate is issued by China chamber of commerce for import and export of medicines and health products, which is not a concern regulatory body. Further the said document does not depict the free availability of the applied product in the country of origin.</p>
M/s Genetics Healthcare, 537-A, Sundar Industrial Estate, Lahore agent of M/s Shandong Yuwang Pharmaceutical Co., Ltd. No.2731 Tonggu Road, Yucheng City, Shandong, China (E. No.00101)		
169.	Sterol –D Stat Capsule	<p>Deferred with final opportunity for the provision of following documents: Free sale certificate is issued by China chamber of commerce for import and export of medicines and health products, which is not a concern regulatory body. Further the said document does depict the free availability of the applied product in the country of origin. Clarification regarding role of gelatin as an active ingredient is required.</p>
M/s Pharma International 204, E.I.Lines, Dr. Daud Pota Road, Karachi agent of M/s Ginsana SA, Via Mulini, CH-6934 Bioggio, Switzerland (E. No.00379)		
170.	Ginsaflex Tablet	<p>Deferred with final opportunity for the provision of following documents:</p> <ul style="list-style-type: none"> Formulation contains glucosamine sulfate and chondroitin sulfate, which are included in the list of common molecules. Provided copy of Free sale certificate does not depict the free availability of the applied product in the country of origin. Provided copy of GMP certificate is not notarized and legalized by the Embassy of Pakistan. Stability Studies data is not provided as per prescribed conditions of Zone IV A.
171.	Gincosan Capsules	<p>Deferred with final opportunity for the provision of following documents:</p> <ul style="list-style-type: none"> Formulation contains glucosamine sulfate and chondroitin sulfate, which are included in the list of common molecules. Provided copy of Free sale certificate does not depict the free availability of the applied product in the country of origin. Provided copy of GMP certificate is not notarized and legalized by the Embassy of Pakistan.

S.No (1)	Brand name (2)	Decision (3)
		<ul style="list-style-type: none"> Stability Studies data is not provided as per prescribed conditions of Zone IV A.
M/s Al-Asar Enterprises, H.No.2574/A, Sarayee Street Justice Hameed Colony, Nishtar Road Multan agent of M/s Veterinary Medicine Import Export Joint Stock Company, Head office: 7, Road 30/4, xuan Khanh ward, Ninh Kieu district, Can Tho City, Vietnam (Veterinary) (E. No. 00411)		
172.	Mucostop	Deferred with final opportunity for provision of following documents: <ul style="list-style-type: none"> Formulation includes Bromhexine HCl which is included in the list of Common molecules. Free sale certificate was expired at the time of provision of application.
173.	Vime-Protex	Deferred with final opportunity for provision of following documents: <ul style="list-style-type: none"> Free sale certificate was expired at the time of provision of application.
M/s Bio Vision Corporation, 88-A, Punjab Cooperative Housing Society (P.C.H.S.), Defence Ghazi Road, Lahore-Pakistan agent of M/s Agritech Service, ZI de Calouet-22600 Loudeac, France [Principal Manufacturer: M/s Alphatech, ZI du Grand Plessis – 22940 Plaintel, France] (E. No. 00648)		
174.	Orgasecure-L	Deferred with final opportunity for provision of following documents: <ul style="list-style-type: none"> Stability studies data provided is not as per prescribed conditions of Zone IV A. Name of Brand Owner is not mentioned on Free sale certificate.
175.	Polflush	Deferred with final opportunity for provision of following documents: <ul style="list-style-type: none"> Stability studies data provided is not as per prescribed conditions of Zone IV A. Name of Brand Owner is not mentioned on Free sale certificate. Formulation contains Dextrose, which is included in the list of common molecules.
176.	Respol Liquid	Deferred with final opportunity for provision of following documents: <ul style="list-style-type: none"> Stability studies data provided is not as per prescribed conditions of Zone IV A. Name of Brand Owner is not mentioned on Free sale certificate.
M/s Physician Select located at the address Plot Number 172-B, Najeeb Centre, 2nd Floor, PECHS, Block-02, Karachi-Pakistan agent of M/s Physician Select Vitamins, 11233 Shadow Creek Parkway, Pearl land, TX, USA [Principal Manufacturer: M/s Randal Optimal Nutrients, 1595 Hampton Way, santa Rosa, California, USA) (E. No. 00770)		
177.	PS Joint Aid Tablet	Deferred since formulation contains common molecule Glucosamine sulfate and Chondroitin sulfate and change of brand name.
M/s MPC Health & Food, SF-13, 5th Floor, Shahnaz Arcade, Main Shaheed-e-Millat Road, Karachi agent of M/s Weihai Baihe Biology Technological Co. Ltd. No. 522, Chengda Toad, Swan Lake Economic Technology Development Zone, Rongcheng, Shandong, China, 264321 (E. No. 00115)		
178.	Menthum Softgel	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> Long term stability studies of Mentum Softgel according to conditions of Zone IV A not provided. GMP certificate has been expired at the time of provision of application for product enlistment. English translation (Menthum softgel) does not match its Chinese language counterpart as given in “Letter of authorization” issued by the principal manufacture, needs clarification in this regards. According the Food Hygiene license issued by Shandong Food and Drug Administration (FDA), mentum softgel is not covered under scope of production and sale health products given to principal manufacture, needs clarification in this regards. English translation of “Food and Drug Administration” does not match with its Chinese Language counterpart as given on copy of letter on subject “Free sales certificate”, needs clarification.
179.	Hurma Tablet	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> Long term stability studies of Mentum Softgel according to conditions of Zone IV A not provided. GMP certificate has been expired at the time of provision of application for product enlistment.

S.No	Brand name	Decision
(1)	(2)	(3)
		<p>English translation (Menthum softgel) does not match its Chinese language counterpart as given in "Letter of authorization" issued by the principal manufacture, needs clarification in this regards.</p> <p>According the Food Hygiene license issued by Shandong Food and Drug Administration (FDA), menthum softgel is not covered under scope of production and sale health products given to principal manufacture, needs clarification in this regards.</p> <p>English translation of "Food and Drug Administration" does not match with its Chinese Language counterpart as given on copy of letter on subject "Free sales certificate", needs clarification.</p>
M/s New Hamdard Medicines, Manan Chowk, M.A. Jinnah Road,87300-Quetta agent of M/s SunlifeProduktions- und Vertriebsgesellschaft, mbH Schierbusch 3.D-33161 Hovelhof, Germany (E. No. 00364)		
180.	Sunlife Diet Drink Balance 500g	<p>Deferred with final opportunity for provision of following documents:</p> <ul style="list-style-type: none"> • Application Form 5 not provided. • Applied brand name is not appropriate. • Product label is not appropriate. • Stability Studies not provided as per prescribed conditions of Zone IV A. • Current Status of GMP compliance of principal manufacturer. • Only Photocopy of Free Sale Certificate is provided and mentioned brand name is different than the applied brand name. • Testing specification of probiotic is required.
181.	Sunlife Panthenol Cream 100ml	<p>Deferred with final opportunity for provision of following documents:</p> <ul style="list-style-type: none"> • The firm has applied three (03) different products i.e. SunlifePanthenol Cream, Sunlife Muscle and Joint Gel and Sunlife Legs and Veins balm on a single dossier with a single fee of Rs. 2000/-. • Application Form 5 not provided. • Applied brand name is not appropriate. • Product label is not appropriate. • Stability Studies not provided as per prescribed conditions of Zone IV A. • Current Status of GMP compliance of principal manufacturer. • Only Photocopy of Free Sale Certificate is provided and mentioned brand name is different than the applied brand name.
182.	Sunlife Energy Drink Effervescent 20 Tablet	<p>Deferred with final opportunity for provision of following documents:</p> <ul style="list-style-type: none"> • Application Form 5 not provided. • Applied brand name is not appropriate. • Product label is not appropriate. • Stability Studies not provided as per prescribed conditions of Zone IV A. • Current Status of GMP compliance of principal manufacturer. • Only Photocopy of Free Sale Certificate is provided and mentioned brand name is different than the applied brand name. • Applied formulation contains Caffeine, which is a drug.
183.	Sunlife Hair Activator Capsule	<p>Deferred with final opportunity for provision of following documents:</p> <ul style="list-style-type: none"> • Application Form 5 not provided. • Applied brand name is not appropriate. • Product label is not appropriate. • Stability Studies not provided as per prescribed conditions of Zone IV A. • Current Status of GMP compliance of principal manufacturer. • Only Photocopy of Free Sale Certificate is provided and mentioned brand name is different than the applied brand name.
184.	Sunlife CalDeSun Osteo Liquid 200ml	<p>Deferred with final opportunity for provision of following documents:</p> <ul style="list-style-type: none"> • Application Form 5 not provided. • Applied brand name is not appropriate.

S.No	Brand name	Decision
(1)	(2)	(3)
		<ul style="list-style-type: none"> Product label is not appropriate. Stability Studies not provided as per prescribed conditions of Zone IV A. Current Status of GMP compliance of principal manufacturer. Only Photocopy of Free Sale Certificate is provided and mentioned brand name is different than the applied brand name.
M/s. AWH Pharma, Plot No. 224/B, Office No. 2, 2nd Floor, Commercial Centre, Satellite Town, Rawalpindi-Pakistan agent of M/s Nutrition Group PLC, 3 Kinraig Court, Kinraig Road Blackpool, FY2 0FY, United Kingdom (E. No. 00199)		
185.	Mutib Caplets	<p>Deferred with final opportunity for provision of following documents:</p> <ul style="list-style-type: none"> Certificate of analysis of finished product reveals that the pack size of Mutib caplet is 30 caplets while given on form 5 is 60 caplets. Test limit as provided in IPQC (Not more than 30 minutes) and COA of finished product (Not more than 15 minutes) w.r.t. disintegration time are not identical to each other, needs clarification. Certificate of analysis of finished product reveals limit of performed assay i.e. Not more than 90%, however according to pharmacopeial specifications assay should be within range of 90%-110% of claimed product. Long term and accelerated stability studies data of atleast 3 batches is required according to the conditions of Zone IV A. Original and valid Free Sale certificate stating name of manufacturer/marketing authorization is required. Valid GMP Certificate issued by regulatory body in country of origin is required, since provided copy of GMP certificate validity has been expired. Form 5 is required to be submitted with name of owner and signature. Following information w.r.t. probiotics cultures are required: Specific bacteria along with strain are required. Characterisation of said probiotic strain is required according to pharmacopeial specifications.
186.	C-Sub Tablet	<p>Deferred with final opportunity for provision of following documents:</p> <ul style="list-style-type: none"> Test limit as provided in IPQC (Not more than 30 minutes) and COA of finished product (Not more than 15 minutes) w.r.t. disintegration time are not identical to each other, needs clarification. Certificate of analysis of finished product reveals limit of performed assay i.e. Not more than 90%, however according to pharmacopeial specifications assay should be within range of 90%-110% of claimed product. Long term and accelerated stability studies data of atleast 3 batches is required according to the conditions of Zone IV A. Original and valid Free Sale certificate stating name of product alongwith its manufacturer/marketing authorization is required. Valid GMP Certificate issued by regulatory body in country of origin is required, since provided copy of GMP certificate validity has been expired. Form 5 is required to be submitted with name of owner and signature.
187.	HSN Tablet	<p>Deferred with final opportunity for provision of following documents:</p> <ul style="list-style-type: none"> Test limit as provided in IPQC (Not more than 30 minutes) and COA of finished product (Not more than 15 minutes) w.r.t. disintegration time are not identical to each other, needs clarification. Certificate of analysis of finished product reveals limit of performed assay i.e. Not more than 90%, however according to pharmacopeial specifications assay should be within range of 90%-110% of claimed product.

S.No (1)	Brand name (2)	Decision (3)
		<ul style="list-style-type: none"> Long term and accelerated stability studies data of atleast 3 batches is required according to the conditions of Zone IV A. Original and valid Free Sale certificate stating name of product alongwith its manufacturer/marketing authorization is required. Valid GMP Certificate issued by regulatory body in country of origin is required, since provided copy of GMP certificate validity has been expired. Form 5 is required to be submitted with name of owner and signature.
188.	Calu-Sub Oil Capsule	<p>Deferred with final opportunity for provision of following documents:</p> <ul style="list-style-type: none"> Test limit as provided in IPQC (Not more than 30 minutes) and COA of finished product (Not more than 15 minutes) w.r.t. disintegration time are not identical to each other, needs clarification. Certificate of analysis of finished product reveals limit of performed assay i.e. Not more than 90%, however according to pharmacopeial specifications assay should be within range of 90%-110% of claimed product. Long term and accelerated stability studies data of atleast 3 batches is required according to the conditions of Zone IV A. Original and valid Free Sale certificate stating name of product alongwith its manufacturer/marketing authorization is required. Valid GMP Certificate issued by regulatory body in country of origin is required, since provided copy of GMP certificate validity has been expired. Form 5 is required to be submitted with name of owner and signature.
189.	RDA 1000 Tablet	<p>Deferred with final opportunity for provision of following documents:</p> <ul style="list-style-type: none"> Test limit as provided in IPQC (Not more than 30 minutes) and COA of finished product (Not more than 15 minutes) w.r.t. disintegration time are not identical to each other, needs clarification. Certificate of analysis of finished product reveals limit of performed assay i.e. Not more than 90%, however according to pharmacopeial specifications assay should be within range of 90%-110% of claimed product. Long term and accelerated stability studies data of atleast 3 batches is required according to the conditions of Zone IV A. Original and valid Free Sale certificate stating name of product alongwith its manufacturer/marketing authorization is required. Valid GMP Certificate issued by regulatory body in country of origin is required, since provided copy of GMP certificate validity has been expired. Form 5 is required to be submitted with name of owner and signature.
190.	Advance Bone Formula Caplets	<p>Deferred with final opportunity for provision of following documents:</p> <ul style="list-style-type: none"> Test limit as provided in IPQC (Not more than 30 minutes) and COA of finished product (Not more than 15 minutes) w.r.t. disintegration time are not identical to each other, needs clarification. Certificate of analysis of finished product reveals limit of performed assay i.e. Not more than 90%, however according to pharmacopeial specifications assay should be within range of 90%-110% of claimed product. Long term and accelerated stability studies data of atleast 3 batches is required according to the conditions of Zone IV A. Original and valid Free Sale certificate stating name of product alongwith its manufacturer/marketing authorization is required. Valid GMP Certificate issued by regulatory body in country of origin is required, since provided copy of GMP certificate validity has been expired.

S.No (1)	Brand name (2)	Decision (3)
		<ul style="list-style-type: none"> Form 5 is required to be submitted with name of owner and signature.
191.	Vialic Caplets	<p>Deferred with final opportunity for provision of following documents:</p> <ul style="list-style-type: none"> Test limit as provided in IPQC (Not more than 30 minutes) and COA of finished product (Not more than 15 minutes) w.r.t. disintegration time are not identical to each other, needs clarification. Certificate of analysis of finished product reveals limit of performed assay i.e. Not more than 90%, however according to pharmacopeial specifications assay should be within range of 90%-110% of claimed product. Long term and accelerated stability studies data of atleast 3 batches is required according to the conditions of Zone IV A. Original and valid Free Sale certificate stating name of product alongwith its manufacturer/marketing authorization is required. Valid GMP Certificate issued by regulatory body in country of origin is required, since provided copy of GMP certificate validity has been expired. Form 5 is required to be submitted with name of owner and signature.
192.	Lituzin Caplets	<p>Deferred with final opportunity for provision of following documents:</p> <ul style="list-style-type: none"> Test limit as provided in IPQC (Not more than 30 minutes) and COA of finished product (Not more than 15 minutes) w.r.t. disintegration time are not identical to each other, needs clarification. Certificate of analysis of finished product reveals limit of performed assay i.e. Not more than 90%, however according to pharmacopeial specifications assay should be within range of 90%-110% of claimed product. Long term and accelerated stability studies data of atleast 3 batches is required according to the conditions of Zone IV A. Original and valid Free Sale certificate stating name of product alongwith its manufacturer/marketing authorization is required. Valid GMP Certificate issued by regulatory body in country of origin is required, since provided copy of GMP certificate validity has been expired. Form 5 is required to be submitted with name of owner and signature.
M/s MPC Health & Food, SF-13, 5th Floor, Shahnaz Arcade, Main Shaheed-e-Millat Road, Karachi agent of M/s Weihai Baihe Biology Technological Co. Ltd. No. 522, Chengda Toad, Swan Lake Economic Technology Development Zone, Rongcheng, Shandong, China, 264321 (E. No. 00115)		
193.	Mpc-D 200000 Softgel	<p>EEC was apprised that Division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the Division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of Division of Health & OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.</p>
194.	Oramax-D Tablet	<p>EEC was apprised that Division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the Division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of Division of Health & OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.</p>

S.No	Brand name	Decision
(1)	(2)	(3)
M/s Aims Health Solutions, 194-N Phase-8, DHA, Lahore Cantt agent of M/s Albors SRL, Via Aurelio Saffi, 9 Milano (operatively in Via Arturo Tosanelli, 14-Buccinasco), Italy. (E. No. 00990)		
195.	Albovit® Hep Super	Deferred with final opportunity for provision of following documents: • Long term stability studies data is required according to conditions of Zone IV A.
196.	Albovit® Selenex Plus	Deferred with final opportunity for provision of following documents: • Long term stability studies data is required according to conditions of Zone IV A.
197.	Albovit® Free Air	Deferred with final opportunity for provision of following documents: • Long term stability studies data is required according to conditions of Zone IV A.
198.	Albovit® Amino Plus	Deferred with final opportunity for provision of following documents: • Long term stability studies data is required according to conditions of Zone IV A.
199.	Albovit® Rehydra	Deferred with final opportunity for provision of following documents: • Long term stability studies data is required according to conditions of Zone IV A.
200.	Albovit® Toxi Stop	Deferred with final opportunity for provision of following documents: • Long term stability studies data is required according to conditions of Zone IV A.
201.	Albovit® Mentholed	Deferred with final opportunity for provision of following documents: • Long term stability studies data is required according to conditions of Zone IV A.
M/s Aves Care, P-63, St.No.3, Umer Housing Scheme Near Younas Town, Satiana Road, Faisalabad agent of M/s Unione Commerciale Lombarda SpA Via G. Di Vittorio 36, 25125 Brescia, Italy (E. No.00645)		
202.	Liqui-Aminoplus Liquid	Deferred with final opportunity for the provision of following documents: • Free sale certificate to be issued by the regulatory body in the country of origin is required. • Long term and accelerated stability studies data is required according to conditions of Zone IV A.
203.	Liqui-ADEK Liquid	Deferred with final opportunity for the provision of following documents: • Free sale certificate to be issued by the regulatory body in the country of origin is required. • Long term and accelerated stability studies data is required according to conditions of Zone IV A.
M/s Forward Solution, located at the address Plot No. 19/B off Abdul Sattar Eidhi Road Near Qazalbash Chowk, Lahore agent of M/s Zinpro Animal Nutrition (international) INC, 10400 Viking Drive – Suite 240 Eden Prairie Mn 55344, USA (E. No. 00801)		
204.	Availa 4	Deferred for Justification required regarding the use of Ground com cob in the formulation.
M/s UM Enterprises located at the address Plot 12, Sector 15, Korangi Industrial Area, Karachi-Pakistan agent of M/s Church & Dwight Co., Inc. 905 South Carolina Ave, Mason City, Iowa, USA (E. No. 00742)		
205.	A-Max Ultra	Deferred for the provision of exact names of the active ingredients along with their role and justification.
206.	Bio-Chlor	Deferred for the provision of exact names of the active ingredients along with their role and justification.
M/s Forward Solution Animal Health Company., located at the address Plot No. 19-B, Off Abdul Sattar Edhi Road, Near Qazalbash Chowk, Lahore agent of M/s Chr. Hansen Czech Republic, Provoz Starovice Land reg.No. 215, Starovice, 693 01, Czech Republic (E. No. 009500)		
207.	Gallipro® Tect	Deferred with the final opportunity for the provision of Free sale certificate issued by the regulatory body clearly showing that the product is freely available in the country of origin.

S.No (1)	Brand name (2)	Decision (3)
M/s Meezab International Jahanian located at the address Near Bilal Mosque, Fareed Abad, Jahanian, Punjab-Pakistan agent of M/s Lexington Enterprises PTE Ltd , 28 Pioneer Crescent #04-14 West Park Bizentral Singapore 6288559, City, Singapore (E. No. 00765)		
208.	Leximix Liquid	Deferred with final opportunity for provision of following documents: • Long term stability studies data is required according to conditions of Zone IV A.
209.	Immunat-A Liquid	Deferred with final opportunity for provision of following documents: • Long term stability studies data is required according to conditions of Zone IV A.
210.	Electrolex Liquid	Deferred with final opportunity for provision of following documents: • Product resembles with ORS formulation, which is added in the list of common molecule. • Long term stability studies data is required according to conditions of Zone IV A.
211.	Reni Protect Liquid	Deferred with final opportunity for provision of following documents: • Justification of Nephromodulators and its testing specification are required. • Justification of Amino Nitrogen and its specifications are required. • Long term stability studies data is required according to conditions of Zone IV A
212.	Lexlyte Liquid	Deferred with final opportunity for provision of following documents: • Justification of Amino Nitrogen and its specifications are required. Long term stability studies data is required according to conditions of Zone IV A.
213.	Livo Pro (Herbal) Liquid	Deferred with final opportunity for provision of following documents: • Long term stability studies data is required according to conditions of Zone IV A. •
M/s Agrilinks, 226, Ravi Block St.No.5, Moiz Town (Salamatpura), Lahore agent of M/s Travipharma B.V. Veemweg 1 3771 MT Barneveld, the Netherlands (E. No. 00448)		
214.	Travi-Lyzo Immune	Deferred with final opportunity for provision of following documents: • COA of finished product stating physical, chemical, and micro biological testing is required. • Long term and accelerated stability studies data is required according to conditions of Zone IV A. • Specific stains of probiotics are required. • The said product is not freely available in the country of Origin as required under provision of SRO 412 (I)/2014.
M/s Nutra Zone health Care, Suite No. 1, Plot No. 58-C, 25th Tauheed Commerical, DHA Phase-5, Karachi (Pincipal manufacturer M/s Thompson & Capper Limited, 1-13 Hardwick Toad, Astmoor Industrial Estate, Runcorn, Cheshire WA7 1PH, United Kingdom (E. No. 0067)		
215.	A To Z Active Effervescent Tablet	Deferred with final opportunity for the provision of following documents: • Form 5 unsigned and unstamped. • Stability studies, COA of finished product and certificate of Free sale bear HealthAid, UK as a principal manufacturer while on form 6 manufacture is M/s Thompson & Capper Limited, 1-13 Hardwick Toad, Astmoor Industrial Estate, Runcorn, Cheshire WA7 1PH, United Kingdom. • Testing Time points of long term stability studies should be every 3 months in first year, every 6 months in second year and every year thereafter. • Evidence stating relationship of M/s Thompson and Capper Limited, UK and M/s HealthAid, UK is required.
216.	Osteozin Tablet	Deferred with final opportunity for the provision of following documents: • Form 5 unsigned and unstamped.

S.No	Brand name	Decision
(1)	(2)	(3)
		<ul style="list-style-type: none"> Stability studies, COA of finished product and certificate of Free sale bear HealthAid, UK as a principal manufacturer while on form 6 manufacture is M/s Thompson & Capper Limited, 1-13 Hardwick Toad, Astmoor Industrial Estate, Runcorn, Cheshire WA7 1PH, United Kingdom. Testing Time points of long term stability studies should be every 3 months in first year, every 6 months in second year and every year thereafter. Evidence stating relationship of M/s Thompson and Capper Limited, UK and M/s HealthAid, UK is required.
217.	Omega 3 750mg Capsule	<p>Deferred with final opportunity for the provision of following documents:</p> <ul style="list-style-type: none"> Form 5 unsigned and unstamped. Stability studies, COA of finished product and certificate of Free sale bear HealthAid, UK as a principal manufacturer while on form 6 manufacture is M/s Thompson & Capper Limited, 1-13 Hardwick Toad, Astmoor Industrial Estate, Runcorn, Cheshire WA7 1PH, United Kingdom. Testing Time points of long term stability studies should be every 3 months in first year, every 6 months in second year and every year thereafter. Evidence stating relationship of M/s Thompson and Capper Limited, UK and M/s HealthAid, UK is required.
218.	Cod Liver Oil 1000mg Capsule	<p>Deferred with final opportunity for the provision of following documents:</p> <ul style="list-style-type: none"> Form 5 unsigned and unstamped. Stability studies, COA of finished product and certificate of Free sale bear HealthAid, UK as a principal manufacturer while on form 6 manufacture is M/s Thompson & Capper Limited, 1-13 Hardwick Toad, Astmoor Industrial Estate, Runcorn, Cheshire WA7 1PH, United Kingdom. Testing Time points of long term stability studies should be every 3 months in first year, every 6 months in second year and every year thereafter. Evidence stating relationship of M/s Thompson and Capper Limited, UK and M/s HealthAid, UK is required.
219.	Coffeeslim Capsule	EEC was apprised that Division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the Division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of Division of Health & OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
M/s Soulm Health Care, located at the address Suit No.1325 Near Khawaja Corporation Adyala Road, Rawalpindi –Pakistan agent of M/s NutraLab Canada Ltd., 980 Tapscott Road Toronto Ontario M1X 1C3 Canada (E. No. 00684)		
220.	Anchovies G Softgel Capsule	<p>Deferred with final opportunity for provision of following documents:</p> <ul style="list-style-type: none"> COAs of raw materials and finished product are required. Long term and accelerated stability studies data is required as per conditions of Zone IV A. Free sale certificate and GMP certificate and agency agreement are required. Testing specification of active ingredients is required.
221.	Oramax D Tablet	<p>Deferred with final opportunity for provision of following documents:</p> <ul style="list-style-type: none"> COAs of raw materials and finished product are required. Long term and accelerated stability studies data is required as per conditions of Zone IV A.

S.No	Brand name	Decision
(1)	(2)	(3)
		<ul style="list-style-type: none"> • Free sale certificate and GMP certificate and agency agreement are required. • Testing specification of active ingredients is required.
222.	Numum Tablet	Deferred with final opportunity for provision of following documents: <ul style="list-style-type: none"> • COAs of raw materials and finished product are required. • Long term and accelerated stability studies data is required as per conditions of Zone IV A. • Free sale certificate and GMP certificate and agency agreement are required. • Testing specification of active ingredients is required.
223.	Maxi Honso Capsule	Deferred with final opportunity for provision of following documents: <ul style="list-style-type: none"> • COAs of raw materials and finished product are required. • Long term and accelerated stability studies data is required as per conditions of Zone IV A. • Free sale certificate and GMP certificate and agency agreement are required. • Testing specification of active ingredients is required.
224.	Quebe Q Capsule	Deferred with final opportunity for provision of following documents: <ul style="list-style-type: none"> • COAs of raw materials and finished product are required. • Long term and accelerated stability studies data is required as per conditions of Zone IV A. • Free sale certificate and GMP certificate and agency agreement are required. • Testing specification of active ingredients is required.
225.	Allkidz Bear Gummy	Deferred with final opportunity for provision of following documents: <ul style="list-style-type: none"> • COAs of raw materials and finished product are required. • Long term and accelerated stability studies data is required as per conditions of Zone IV A. • Free sale certificate and GMP certificate and agency agreement are required. • Testing specification of active ingredients is required.
226.	Allkidz Probiotic Gummy	Deferred with final opportunity for provision of following documents: <ul style="list-style-type: none"> • COAs of raw materials and finished product are required. • Long term and accelerated stability studies data is required as per conditions of Zone IV A. • Free sale certificate and GMP certificate and agency agreement are required. • Testing specification of active ingredients is required.
227.	Allkids Probiotic Liquid	Deferred with final opportunity for provision of following documents: <ul style="list-style-type: none"> • COAs of raw materials and finished product are required. • Long term and accelerated stability studies data is required as per conditions of Zone IV A. • Free sale certificate and GMP certificate and agency agreement are required. • Testing specification of active ingredients is required.
228.	G2X B Capsule	Deferred with final opportunity for provision of following documents: <ul style="list-style-type: none"> • COAs of raw materials and finished product are required. • Long term and accelerated stability studies data is required as per conditions of Zone IV A. • Free sale certificate and GMP certificate and agency agreement are required. • Testing specification of active ingredients is required.
229.	Sealoba Softgel Capsule	Deferred with final opportunity for provision of following documents: <ul style="list-style-type: none"> • COAs of raw materials and finished product are required. • Long term and accelerated stability studies data is required as per conditions of Zone IV A. • Free sale certificate and GMP certificate and agency agreement are required. • Testing specification of active ingredients is required.

S.No (1)	Brand name (2)	Decision (3)
230.	Nutrex Plus Syrup	EEC was apprised that Division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the Division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of Division of Health & OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
M/s Indus Pharma (Pvt.) Ltd., located at the address Plot 65/27, Korangi Industrial Area, Karachi agent of M/s Krafticus Koordination GmbH, Grostrowstr.1 66740, Saarouis, Germany (E. No. 00861)		
231.	ISN 100% Whey Protein Concentrate-Strawberry Banana	Deferred with final opportunity for provision of following documents: <ul style="list-style-type: none"> • Source of Fat, carbohydrate and protein is required. • Signed and Stamped form 5 is required. • Long term and accelerated stability studies data is required as per conditions of Zone IV A. • Original and valid Free sale certificate issued by the regulatory body in the country of origin. • Pharmaceutical dosage form in which product is formulated, is required. • Brand name mentioned on form 5 (ISN 100% Whey Protein Concentrate-Strawberry Banana) and on Free sale certificate (Whey Protein Concentrate-Strawberry Banana) are not identical to each other, needs clarification. • Pack size mentioned on form 5 (2lbs with 27 servings) and on free sale certificate (908g) are different from each other, needs clarification.
232.	ISN 100% Whey Protein Concentrate-Chocolate	Deferred with final opportunity for provision of following documents: <ul style="list-style-type: none"> • Source of Fat, carbohydrate and protein is required. • Signed and Stamped form 5 is required. • Long term and accelerated stability studies data is required as per conditions of Zone IV A. • Original and valid Free sale certificate issued by the regulatory body in the country of origin. • Pharmaceutical dosage form in which product is formulated, is required. • Brand name mentioned on form 5 (ISN 100% Whey Protein Concentrate-Chocolate) and on Free sale certificate (Whey Protein Concentrate-Chocolate) are not identical to each other, needs clarification. • Pack size mentioned on form 5 (2lbs with 27 servings) and on free sale certificate (908g) are different from each other, needs clarification.
233.	Impact Pre-Workout by ISN – Wild Berries	Deferred with final opportunity for provision of following documents: <ul style="list-style-type: none"> • Source of Fat, carbohydrate and protein is required. • Signed and Stamped form 5 is required. • Long term and accelerated stability studies data is required as per conditions of Zone IV A. • Original and valid Free sale certificate issued by the regulatory body in the country of origin. • Pharmaceutical dosage form in which product is formulated, is required. • Brand name mentioned on form 5 (Impact Pre-Workout by ISN – Wild Berries) and on Free sale certificate and COA (Pre-workout fat burner Berries) are not identical to each other, needs clarification. • Pack size mentioned on form 5 (500g) and on free sale certificate (270g) are different from each other, needs clarification. • Caffeine is included in the list of common molecule.

S.No	Brand name	Decision
(1)	(2)	(3)
234.	ISN Protein Oats – Caramel	<p>Deferred with final opportunity for provision of following documents:</p> <ul style="list-style-type: none"> • Source of Fat, carbohydrate and protein is required. • Signed and Stamped form 5 is required. • Long term and accelerated stability studies data is required as per conditions of Zone IV A. • Original and valid Free sale certificate issued by the regulatory body in the country of origin. • Pharmaceutical dosage form in which product is formulated is required. • Brand name mentioned on form 5 (ISN Protein Oats – Caramel) and on Free sale certificate (Porridge Caramel) are not identical to each other, needs clarification.
M/s Olio Pharma located at the address 114-E Valancia Society, Lahore –Pakistan agent of M/s Nutralab Canada Ltd., 980 Tapscott Road, Toronto, ON M1X 1C3 Canada (E. No. 00680)		
235.	Activia Men’s Formula Tablet	<p>Deferred with final opportunity for the provision of following documents:</p> <ul style="list-style-type: none"> • Long term and accelerated stability studies data is required as per conditions of Zone IV A. • Applied dosage form is tablet while Activia Men’s Formula is being formulated in caplet, needs clarification in this regard. • Prescribed Form 5 under SRO 412 is required. • Applied Brand Name is Men’s Formula whereas COA of finished product bears Activia Men’s Formula as brand name, needs clarification. • Free sale certificate is issued by regulatory body in the country of origin is required.
236.	Activia Women’s Formula Tablet	<p>Deferred with final opportunity for the provision of following documents:</p> <ul style="list-style-type: none"> • Long term and accelerated stability studies data is required as per conditions of Zone IV A. • Applied dosage form is tablet while Activia Men’s Formula is being formulated in caplet, needs clarification in this regard. • Prescribed Form 5 under SRO 412 is required. • Applied Brand Name is Men’s Formula whereas COA of finished product bears Activia Men’s Formula as brand name, needs clarification. • Free sale certificate is issued by regulatory body in the country of origin is required.
237.	Vigomate Capsule	<p>Deferred with final opportunity for the provision of following documents:</p> <ul style="list-style-type: none"> • Long term and accelerated stability studies data is required as per conditions of Zone IV A. • Applied dosage form is tablet while Activia Men’s Formula is being formulated in caplet, needs clarification in this regard. • Prescribed Form 5 under SRO 412 is required. • Applied Brand Name is Men’s Formula whereas COA of finished product bears Activia Men’s Formula as brand name, needs clarification. • Free sale certificate is issued by regulatory body in the country of origin is required.
M/s Green World Food Wholesales Co. (Pvt) Ltd.,Mezzanine Floor, 29-B, Mid-City Mall, Main Murree Road, Rawalpindi agent of M/s World (Tianjin) Nutrition Health Food Co., Ltd., China (E. No. 00363)		
238.	Deep Sea Fish Oil Capsule (Omega-3)	<p>Deferred with final opportunity for the provision of following documents:</p> <ul style="list-style-type: none"> • Long term and accelerated stability studies data is required as per conditions of Zone IV A.

S.No (1)	Brand name (2)	Decision (3)
		<ul style="list-style-type: none"> Free sale certificate issued by the regulatory body and countersigned by the embassy of Pakistan in the country of origin. Testing specification of active ingredient (Deep sea fish oil) is required.
239.	Lecithin Capsule	<p>Deferred with final opportunity for the provision of following documents:</p> <ul style="list-style-type: none"> Long term and accelerated stability studies data is required as per conditions of Zone IV A. Free sale certificate issued by the regulatory body and countersigned by the embassy of Pakistan in the country of origin. Brand name to be changed.
240.	Kidney Tonifying Capsule (Men)	<p>Deferred with final opportunity for the provision of following documents:</p> <ul style="list-style-type: none"> Long term and accelerated stability studies data is required as per conditions of Zone IV A. Free sale certificate issued by the regulatory body and countersigned by the embassy of Pakistan in the country of origin. Testing specification of active ingredient is required. Brand name to be changed.
241.	Kidney Tonifying Capsule (Women)	<p>Deferred with final opportunity for the provision of following documents:</p> <ul style="list-style-type: none"> Long term and accelerated stability studies data is required as per conditions of Zone IV A. Free sale certificate issued by the regulatory body and countersigned by the embassy of Pakistan in the country of origin. Testing specification of active ingredient is required. Brand name to be changed.
242.	Joint Health Plus Capsule	<p>Deferred with final opportunity for the provision of following documents:</p> <ul style="list-style-type: none"> Long term and accelerated stability studies data is required as per conditions of Zone IV A. Free sale certificate issued by the regulatory body and countersigned by the embassy of Pakistan in the country of origin. Testing specification of active ingredient is required. Brand name to be changed.
243.	Detoxin Pad	<p>Deferred with final opportunity for the provision of following documents:</p> <ul style="list-style-type: none"> Long term and accelerated stability studies data is required as per conditions of Zone IV A. Free sale certificate issued by the regulatory body and countersigned by the embassy of Pakistan in the country of origin. Testing specification of active ingredient is required. Brand name to be changed.
244.	Zinc Tablet (for Adults)	<p>Deferred with final opportunity for the provision of following documents:</p> <ul style="list-style-type: none"> Long term and accelerated stability studies data is required as per conditions of Zone IV A. Free sale certificate issued by the regulatory body and countersigned by the embassy of Pakistan in the country of origin. Testing specification of active ingredient is required. Brand name to be changed.
245.	Zinc Tablet (for Children)	<p>Deferred with final opportunity for the provision of following documents:</p> <ul style="list-style-type: none"> Long term and accelerated stability studies data is required as per conditions of Zone IV A. Free sale certificate issued by the regulatory body and countersigned by the embassy of Pakistan in the country of origin. Testing specification of active ingredient is required.

S.No (1)	Brand name (2)	Decision (3)
		<ul style="list-style-type: none"> • Brand name to be changed. •
246.	Calcium Tablet	<p>Deferred with final opportunity for the provision of following documents:</p> <ul style="list-style-type: none"> • Long term and accelerated stability studies data is required as per conditions of Zone IV A. • Free sale certificate issued by the regulatory body and countersigned by the embassy of Pakistan in the country of origin. • Testing specification of active ingredient is required. • Brand name to be changed. •
247.	Ganoderma Plus Capsule	<p>Deferred with final opportunity for the provision of following documents:</p> <ul style="list-style-type: none"> • Long term and accelerated stability studies data is required as per conditions of Zone IV A. • Free sale certificate issued by the regulatory body and countersigned by the embassy of Pakistan in the country of origin. • Testing specification of active ingredient is required. • Brand name to be changed. •
248.	Super Nutrition Powder	<p>Deferred with final opportunity for the provision of following documents:</p> <ul style="list-style-type: none"> • Long term and accelerated stability studies data is required as per conditions of Zone IV A. • Free sale certificate issued by the regulatory body and countersigned by the embassy of Pakistan in the country of origin. • Testing specification of active ingredient is required. • Brand name to be changed. •
M/s Tradelink, 45-D, Block-6, PECHS, Karachi-Pakistan agent of M/s Martin Dow HealthCare 1 Rue Antoine Lavoisier 45500 GIEN, France (E. No. 00483)		
249.	Prostaprotect Capsule	<p>Deferred with final opportunity for the provision of following documents:</p> <ul style="list-style-type: none"> • Long term and accelerated stability studies data is required as per conditions of Zone IV A. • Free sale certificate is issued by regulatory body in the country of origin is required. • License and GMP Certificate is required.
250.	Lutaviz Sticks	<p>Deferred with final opportunity for the provision of following documents:</p> <ul style="list-style-type: none"> • Long term and accelerated stability studies data is required as per conditions of Zone IV A. • Free sale certificate is issued by regulatory body in the country of origin is required. • License and GMP Certificate is required.
251.	Osteolock Tablets	<p>Deferred with final opportunity for the provision of following documents:</p> <ul style="list-style-type: none"> • Long term and accelerated stability studies data is required as per conditions of Zone IV A. • Free sale certificate is issued by regulatory body in the country of origin is required. • License and GMP Certificate is required.
252.	Caldow Chewable Tablet	<ul style="list-style-type: none"> •
i. M/s Schiwo Pakistan located at the address 11-G, Shah Rukan-e-Alam Colony, Multan –Pakistan agent of M/s Zhengzhou Bairui Animal Pharmaceutical Co., Ltd., Xinzhen City Baqiangxian on the North Side of The Xin Chun Road No.2, China (E. No. 00687)		
253.	Bory-Intestinal Activator	<p>Deferred with final opportunity for the provision of following documents:</p> <ul style="list-style-type: none"> • Long Term Stability studies data submitted is not according to the requirements of Zone IV A.

S.No	Brand name	Decision
(1)	(2)	(3)
254.	Bory-Flojin	Deferred with final opportunity for the provision of following documents: • Long Term Stability studies data submitted is not according to the requirements of Zone IV A.
255.	Bory-ADEK Powder	Deferred with final opportunity for the provision of following documents: • Long Term Stability studies data submitted is not according to the requirements of Zone IV A.
256.	Bory-Butyricon	Deferred with final opportunity for the provision of following documents: • Long Term Stability studies data submitted is not according to the requirements of Zone IV A.
257.	Bory-Chelphos	Deferred with final opportunity for the provision of following documents: • Long Term Stability studies data submitted is not according to the requirements of Zone IV A.
258.	Bory-Copper Max	Deferred with final opportunity for the provision of following documents: • Long Term Stability studies data submitted is not according to the requirements of Zone IV A.
M/s Schiwo Pakistan, Office No. 10, 1st Floor, City Plaza, Khanawal Road, Multan agent of M/s Asifac Viet Pharma Co., Ltd., No. 220, Pham the Hien St. Ward 2, Dist. 8, Hochiminh City, Vietnam (E. No. 0013)		
259.	ASI-Mirus	Deferred with final opportunity for the provision of following documents: • COA of finished product stating assay of all active ingredients, is required. • Testing specification of Origanum vulgare and Eucalyptus Globulus are required. • Long term and accelerated stability studies data is required as per conditions of Zone IV A.
M/s Ghazi Brothers, Ghazi House, D-35, KDA Cheme # 1, Miran Muhammad Shah Road, Karachi-75350 (Veterinary) agent of M/s Artimon, 5, Rue Brindejone de la Moulinais 22190 PLERIN, France (E. No. 00385)		
260.	Securitor	Deferred with final opportunity for the provision of following documents: • Long term stability studies data is required as per conditions of Zone IV A.
M/s Zuram Brothers located at the address 522 Hmanza Block, Street No 6, Green View Colony, Faisalabad-Pakistan agent of M/s Yem-Vit Vitaminli Yem Katki Mad, San. Ve tic. A.S. Ankara Asfalti Ali Kocer Sit. No: 89/21 35170 Kemalpasas – Izmir Turkey (E. No. 00751)		
261.	Eurogen Nitro	Deferred with final opportunity for provision of following documents: • Long term stability studies data is required according to conditions of Zone IV A of Three (03) Batches.
262.	Vitator	Deferred with final opportunity for provision of following documents: Long term stability studies data is required according to conditions of Zone IV A of Three (03) Batches.
263.	Eurosacc	Deferred with final opportunity for provision of following documents: Long term stability studies data is required according to conditions of Zone IV A of Three (03) Batches.
264.	Eurosal	Deferred with final opportunity for provision of following documents: • Long term stability studies data is required according to conditions of Zone IV A of Three (03) Batches.
265.	Eurotox	Deferred with final opportunity for provision of following documents: • Long term stability studies data is required according to conditions of Zone IV A of Three (03) Batches.
M/s Zuram Brothers, located at the address 522-Hamza Block, Street No. 6, Green View Colony, Faisalabad agent of M/s Artan, 35 rue Paul Bomer, 22 950 Tregueux- France (Principle Manufacturer M/s Artimon, 5 rue Brindejone des Moulinais – 22190, Plerin, France) (E. No. 00958)		
266.	Immunosol-200 (Oral Solution/Liquid)	Deferred with final opportunity for provision of following documents:

S.No	Brand name	Decision
(1)	(2)	(3)
		<ul style="list-style-type: none"> Long term stability studies data is required according to conditions of Zone IV A of three batches. COA of finished product of all ingredients is required.
M/s AgroVisions 72-B Peoples Colony No.1 Faislabad agent of M/s MIAVIT GmbH, Robert-Bosch-Strasse 3, 49632 Essen – Germany (E. No. 00889)		
267.	HD 545 Extra	<p>Deferred with final opportunity for provision of following documents:</p> <ul style="list-style-type: none"> Evidence stating Lower Saxony State for Consumer Protection and Food Safety is itself regulatory body or authorized by concern department in the country of origin. Valid Agency agreement if required. Long term and accelerated stability studies data is required according to conditions of Zone IV A.
M/s IBL Healthcare (Pvt) Ltd., located at the address 9th floor, N.I.C.L Building, Abbasi Shaheed Road, Karachi-Pakistan agent of M/s Belourthe S.A. Avenue des Villas 3 4180 Hamoir, Belgium (E. No. 00667)		
268.	Prep-Up Wheat Milk Honey	<p>Deferred with final opportunity for the provision of following documents:</p> <ul style="list-style-type: none"> Signed and Stamped prescribed Form 5 is required. Brand name to be specified. While certificate for registration issued by Federal agency for safety of Food Chain, Kingdom of Belgium bears brand name as Pre-Up Honey Cereal. Long term and accelerated stability studies data is required according to conditions of Zone IV A. COA of finished product is required. Last inspection report/GMP certificate is required
269.	Prep-Up Rice Milk	<p>Deferred with final opportunity for the provision of following documents:</p> <ul style="list-style-type: none"> Signed and Stamped prescribed Form 5 is required. Brand name to be specified. While certificate for registration issued by Federal agency for safety of Food Chain, Kingdom of Belgium bears brand name as Pre-Up Honey Cereal. Long term and accelerated stability studies data is required according to conditions of Zone IV A. COA of finished product is required. Last inspection report/GMP certificate is required
270.	Prep-Up Wheat Milk	<p>Deferred with final opportunity for the provision of following documents:</p> <ul style="list-style-type: none"> Signed and Stamped prescribed Form 5 is required. Brand name to be specified. While certificate for registration issued by Federal agency for safety of Food Chain, Kingdom of Belgium bears brand name as Pre-Up Honey Cereal. Long term and accelerated stability studies data is required according to conditions of Zone IV A. COA of finished product is required. Last inspection report/GMP certificate is required
271.	Prep-Up Wheat Milk-5 Fruits	<p>Deferred with final opportunity for the provision of following documents:</p> <ul style="list-style-type: none"> Signed and Stamped prescribed Form 5 is required. Brand name to be specified. While certificate for registration issued by Federal agency for safety of Food Chain, Kingdom of Belgium bears brand name as Pre-Up Honey Cereal. Long term and accelerated stability studies data is required according to conditions of Zone IV A. COA of finished product is required. Last inspection report/GMP certificate is required
M/s IBL Healthcare (Pvt) Ltd., located at the address 9th floor, N.I.C.L Building, Abbasi Shaheed Road, Karachi-Pakistan agent of M/s Mead Johnson B.V. Middenkampweg 2, 6545 CJ Nijmegen, Netherland (E. No. 00668)		
272.	Enfamil O-Lac	<p>Deferred with final opportunity for the provision of following documents:</p> <ul style="list-style-type: none"> Long term and accelerated stability studies data is required according to conditions of Zone IV A.

S.No	Brand name	Decision
(1)	(2)	(3)
		<ul style="list-style-type: none"> • Free sale certificate issued by regulatory body in the country of origin. • Source of Fats and protein is required. • Sub type of Vitamin K is required, since vitamin K3 is banned due to adverse effects.
273.	Enfamil A	<p>Deferred with final opportunity for the provision of following documents:</p> <ul style="list-style-type: none"> • Long term and accelerated stability studies data is required according to conditions of Zone IV A. • Free sale certificate issued by regulatory body in the country of origin. • Source of Fats and protein is required. • Sub type of Vitamin K is required, since vitamin K3 is banned due to adverse effects.
274.	Enfamil A+ Premature Formula	<p>Deferred with final opportunity for the provision of following documents:</p> <ul style="list-style-type: none"> • Long term and accelerated stability studies data is required according to conditions of Zone IV A. • Free sale certificate issued by regulatory body in the country of origin. • Source of Fats and protein is required. • Sub type of Vitamin K is required, since vitamin K3 is banned due to adverse effects.
M/s IBL Healthcare (Pvt) Ltd., 9th floor, N.I.C.L. Building Abbasi Shaheed Road, Karachi agent of M/s MEAD JOHNSON NUTRITION (THAILAND) 700/428 Moo 7, Amata Nakorn Industrial Estate, Phase 4, Tambon Don Huaroh, Amphoe Mueang Chon Buri, Changwat Chon Buri, Thailand (E. No. 00521)		
275.	Enfamama A+ Vanilla	<p>Deferred with final opportunity for the provision of following documents:</p> <ul style="list-style-type: none"> • Long term and accelerated stability studies data is required according to conditions of Zone IV A. • Free sale certificate issued by Food and Drug Administration Thailand does not reveal that said product is freely available in the country of origin, needs clarification. • Manufacturing license, GMP certificate, last inspection report and agency agreement are required. • Sub type of Vitamin K is required, since vitamin K3 is banned due to adverse effects.
276.	Enfamama A+ Chocolate	<p>Deferred with final opportunity for the provision of following documents:</p> <ul style="list-style-type: none"> • Long term and accelerated stability studies data is required according to conditions of Zone IV A. • Free sale certificate issued by Food and Drug Administration Thailand does not reveal that said product is freely available in the country of origin, needs clarification. • Manufacturing license, GMP certificate, last inspection report and agency agreement are required. • Sub type of Vitamin K is required, since vitamin K3 is banned due to adverse effects.
277.	Enfagrow A+ Stage 4	<p>Deferred with final opportunity for the provision of following documents:</p> <ul style="list-style-type: none"> • Long term and accelerated stability studies data is required according to conditions of Zone IV A. • Free sale certificate issued by Food and Drug Administration Thailand does not reveal that said product is freely available in the country of origin, needs clarification. • Manufacturing license, GMP certificate, last inspection report and agency agreement are required. • Sub type of Vitamin K is required, since vitamin K3 is banned due to adverse effects.
278.	Enfamil A+ Stage 1	<p>Deferred with final opportunity for the provision of following documents:</p>

S.No	Brand name	Decision
(1)	(2)	(3)
		<ul style="list-style-type: none"> Long term and accelerated stability studies data is required according to conditions of Zone IV A. Free sale certificate issued by Food and Drug Administration Thailand does not reveal that said product is freely available in the country of origin, needs clarification. Manufacturing license, GMP certificate, last inspection report and agency agreement are required.
279.	Enfamil A+ Stage 2	<p>Deferred with final opportunity for the provision of following documents:</p> <ul style="list-style-type: none"> Long term and accelerated stability studies data is required according to conditions of Zone IV A. Free sale certificate issued by Food and Drug Administration Thailand does not reveal that said product is freely available in the country of origin, needs clarification. Manufacturing license, GMP certificate, last inspection report and agency agreement are required.
280.	Enfagrow A+ Stage 3	<p>Deferred with final opportunity for the provision of following documents:</p> <ul style="list-style-type: none"> Long term and accelerated stability studies data is required according to conditions of Zone IV A. Free sale certificate issued by Food and Drug Administration Thailand does not reveal that said product is freely available in the country of origin, needs clarification. Manufacturing license, GMP certificate, last inspection report and agency agreement are required.
M/s IBL Health Care (Pvt) Ltd, 9th Floor, N.I.C.L, Building Abbasi Shaheed Road, Karachi agent of M/s.Principal Health Care Ltd, Airedale Business Centre, Millennium Road, Skipton, North Yorkshire, UK (E. No. 00280)		
281.	Essential Plus + Tablet	<p>Deferred with final opportunity for the provision of following documents:</p> <ul style="list-style-type: none"> Long term and accelerated stability studies data is required according to conditions of Zone IV A. Free sale certificate issued by the secretary of state for environment, Food and Rural Affairs does not depicted the name of any principal manufacturer/marketing authorization holder nor submitted any document by the importer which reveals marketing authorization rights of the said product.M/s Principal Health care Ltd., UK (Principal Manufacturer) has changed its name to M/s Health Innovations Ltd., UK having same manufacturing address, in this regards manufacturing license stating new name of manufacturing site is required.
M/s Jawad Impex International, 21-Iftikhar Building, Chouburji, Lahore agent of M/s Zagro Singapore Pte Ltd Zagro Global Hub 5 Woodlands Terrace Singapore 738460 (E. No. 00113)		
282.	Zagromix Forte 0.1% - Premix	<p>Deferred with final opportunity for provision of following documents:</p> <ul style="list-style-type: none"> Stability Studies data stating physical and microbial testing parameters is required. Stability studies data (long term) to be submitted of atleast 24 months for issuance of shelf life of 2 years.
M/s Genetics Healthcare, 537-A Sundar Industrial Estate, Raiwind Road, Lahore agent of M/s BioGrowing Co. Ltd. No. 10666, Songze Rd, Qingpu, Shanghai, 201700, CHINA (E. No. 00103)		
283.	Braxis Sachet	<p>Deferred with final opportunity for provision of following documents:</p> <ul style="list-style-type: none"> Long term and accelerated stability studies data is required according to conditions of Zone IV A. Free sale certificate issued by regulatory body in the country of origin is required.
284.	Orabiol Sachet	Deferred with final opportunity for provision of following documents:

S.No (1)	Brand name (2)	Decision (3)
		<ul style="list-style-type: none"> Long term and accelerated stability studies data is required according to conditions of Zone IV A. Free sale certificate issued by regulatory body in the country of origin is required.
M/s Better Traders International located at the address 23-Z, Saifullah Shaheed Road Madina Town, Faisalabad-Pakistan agent of M/s Kiotechagil International PLC(Now Rebranded as Anpario PLC, Unit 5-6 manton Wood Enterprise Park Workshop, Nottighamshire S80 2RS, United Kingdom) (E. No. 00747)		
285.	Mycostat	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> Long term and accelerated stability studies data is required according to conditions of Zone IV A. GMP Certificate is issued by regulatory body is not provided.
286.	MasterCube	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> Long term and accelerated stability studies data is required according to conditions of Zone IV A. GMP Certificate is issued by regulatory body is not provided.
287.	Meriphyze 5000	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> Long term and accelerated stability studies data is required according to conditions of Zone IV A. GMP Certificate is issued by regulatory body is not provided.
288.	Salkil Liquid	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> Long term and accelerated stability studies data is required according to conditions of Zone IV A. GMP Certificate is issued by regulatory body is not provided.
289.	Optomega Plus	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> Long term and accelerated stability studies data is required according to conditions of Zone IV A. GMP Certificate is issued by regulatory body is not provided.
290.	pHorce	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> Long term and accelerated stability studies data is required according to conditions of Zone IV A. GMP Certificate is issued by regulatory body is not provided.
291.	Meriphyze 10000	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> Long term and accelerated stability studies data is required according to conditions of Zone IV A. GMP Certificate is issued by regulatory body is not provided.
M/s Aim Corporation, first floor Jhelum motor GT Road, Jhelum-Pakistan agent of M/s Bactolac Pharmaceutical, Inc. 7 Oser Ave, Hauppauge, New York, USA (E.No. 00559)		
292.	Move Easy(250 Tablets)	Deferred with final opportunity for the submission of following documents: <ul style="list-style-type: none"> Glucosamine and Chondroitin and Hyaluronic acid are included in the list of common molecule. Long term and accelerated stability studies data is required according to conditions of Zone IV A. Free sale certificate issued by the regulatory body in the country of origin is required.

S.No	Brand name	Decision
(1)	(2)	(3)
		<ul style="list-style-type: none"> • Manufacturing license and GMP issued by the regulatory body in the country of origin.
293.	L-Carnitine	<p>Deferred with final opportunity for the submission of following documents:</p> <ul style="list-style-type: none"> • Long term and accelerated stability studies data is required according to conditions of Zone IV A. • Free sale certificate issued by the regulatory body in the country of origin is required. • Manufacturing license and GMP issued by the regulatory body in the country of origin.
M/s Zenith (Pvt) Ltd., located at the address office No.406, Faiyaz Center, SMCHS, Shahrah-e-Faisal, Karachi-Pakistan agent of M/s Sanotact GmbH Hessenweg 10, Munster Germany (E.No. 00787)		
294.	Hansal Dairy Digest Lactase	<p>Deferred with final opportunity for the provision of following documents:</p> <ul style="list-style-type: none"> • Lactase is added in the list of common molecule. • Evidence stating hila source of Fat and protein is required. • COA of finished product stating chemical assay and microbiological testing, is required. • Long term and accelerated stability studies data is required according to conditions of Zone IV A. • Last inspection report of principal manufacturer issued by regulatory body in the country of origin is required. • Original and valid Free Sale certificate is required.
295.	Sanotact Magnesium Citrate Sachet	<p>Deferred with final opportunity for the provision of following documents:</p> <ul style="list-style-type: none"> • Strength of Magnesium Citrate per serving dose to be rationalized according to RDA limit of elemental magnesium. • Long term and accelerated stability studies data is required according to conditions of Zone IV A. • Last inspection report of principal manufacturer is required. • Last inspection report of principal manufacturer issued by regulatory body in the country of origin is required. • COA of finished product is required.
296.	Hansal Vitamin C 1000	<p>Deferred with final opportunity for the provision of following documents:</p> <ul style="list-style-type: none"> • Long term and accelerated stability studies data is required according to conditions of Zone IV A. • Last inspection report of principal manufacturer issued by regulatory body in the country of origin is required. • COA of finished product is required. • Original and valid Free Sale certificate is required.
297.	Intact Gluco Tablet Raspberry Flavour	<p>Deferred with final opportunity for the provision of following documents:</p> <ul style="list-style-type: none"> • Dextrose is included in the list of common molecules. • Long term and accelerated stability studies data is required according to conditions of Zone IV A. • Last inspection report of principal manufacturer issued by regulatory body in the country of origin is required. • COA of finished product is required. • Original and valid Free Sale certificate is required.
298.	Hansal A-Z Vital Caplet	<p>Deferred with final opportunity for the provision of following documents:</p> <ul style="list-style-type: none"> • Long term and accelerated stability studies data is required according to conditions of Zone IV A. • Last inspection report of principal manufacturer issued by regulatory body in the country of origin is required. • COA of finished product is required. • Original and valid Free Sale certificate is required.

S.No	Brand name	Decision
(1)	(2)	(3)
M/s Jacked Nutrition, Shop No. 2 and 3, Ground Floor, Commercial Plaza No. 1 Multi Arcade, E-11/1, Islamabad agent of M/s Blade Sport Kft. HU 1055 Budapest, Nyugati Square 6, Hungary (Principal Manufacturer M/s Elelmiszeripari Kft. Pinkeret 1, H-9142, Rabapatona, Hungary) (E. No. 010183)		
299.	Blade Pro Series V-Pack	Deferred since formulation contains: <ul style="list-style-type: none"> • Glucosamine and chondroitin are included in the list of common molecule. • Pack size does not relate with applied formulation.
M/s Poulvet Tradings, Flat # T-5, Shabnam Centre, Shalimar Link Road, Mughalpura, Lahore-Pakistan agent of M/s Vimar Gida Tarim VE Hayvancilik San. Tic. A.S., Istanbul Anadolu Yakasi Org. San. Bolgesi Aydinli Mah.2, San. Cad. No.16 Tuzla Istanbul, Turkey (Veterinary) (E. No. 00616)		
300.	Moldcid Liquid	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> • COA of finished product bears following statement: • Moldcid Liquid is used to control the reproduction of mold, Fungi and bacteria. • Clarification is required either the said formulation is intended for above mention recommended use falls under preview of Health products as given in SRO 412. • COA does not show test results of any parameters (physical, chemical and microbial) needs clarification in this regards. • Long term and accelerated stability studies data is required according to conditions of Zone IV A. • GMP Certificate issued by the regulatory body in the country of origin. • Free sale certificate, last inspection report (issued by regulatory body in the country of origin) and agency agreement is required.
301.	Garlforce	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> • Long term and accelerated stability studies data is required according to conditions of Zone IV A. • GMP Certificate issued by the regulatory body in the country of origin. • Free sale certificate, last inspection report (issued by regulatory body in the country of origin) and agency agreement is required.
302.	Vimarmix Eurovit Liquid	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> • Long term and accelerated stability studies data is required according to conditions of Zone IV A. • GMP Certificate issued by the regulatory body in the country of origin. • Free sale certificate, last inspection report (issued by regulatory body in the country of origin) and agency agreement is required.
303.	Vimarmix Aminovit	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> • Long term and accelerated stability studies data is required according to conditions of Zone IV A. • GMP Certificate issued by the regulatory body in the country of origin. • Free sale certificate, last inspection report (issued by regulatory body in the country of origin) and agency agreement is required.
M/s Multicare International Company (SMC PRIVATE) LIMITED located at the address A-99 Ittefaq Town Road, Near Bohistaan Masjid Sector G-12 Islamabad agent of M/s Shijiazhuang ZDHF Stock Raising Co., Ltd. office No. 260-1 Heping East Road, Shijiazhuang City Hebei Province China. Factory address No 1 yinhai road weixian county industry district Xingtai city Hebei China (E. No. 00843)		
304.	Multi IB Saver Powder	Deferred with final opportunity for the submission of following documents: <ul style="list-style-type: none"> • Prescribed form 5 is required. • Brand name to be changed and alternate name to be provided by the principal manufacturer on its official letter head.

S.No (1)	Brand name (2)	Decision (3)
		<ul style="list-style-type: none"> • Free sale certificate issued by the regulatory body in the country of origin, is required. • GMP certificate issued by the regulatory body in the country of origin is required. • Testing specifications of raw materials and finished product is required. • Long term and accelerated stability studies data is required according to conditions of Zone IV A. • COA of raw materials and Finished product is required. • Agency agreement is required.
305.	Multi Mint Oral Solution	<p>Deferred with final opportunity for the submission of following documents:</p> <ul style="list-style-type: none"> • Prescribed form 5 is required. • Brand name to be changed and alternate name to be provided by the principal manufacturer on its official letter head. • Free sale certificate issued by the regulatory body in the country of origin, is required. • GMP certificate issued by the regulatory body in the country of origin is required. • Testing specifications of raw materials and finished product is required. • Long term and accelerated stability studies data is required according to conditions of Zone IV A. • COA of raw materials and Finished product is required. • Agency agreement is required.
306.	Multi Lyzo Powder	<p>Deferred with final opportunity for the submission of following documents:</p> <ul style="list-style-type: none"> • Prescribed form 5 is required. • Brand name to be changed and alternate name to be provided by the principal manufacturer on its official letter head. • Free sale certificate issued by the regulatory body in the country of origin, is required. • GMP certificate issued by the regulatory body in the country of origin is required. • Testing specifications of raw materials and finished product is required. • Long term and accelerated stability studies data is required according to conditions of Zone IV A. • COA of raw materials and Finished product is required. • Agency agreement is required.
307.	Mutli Anti Virus Oral Solution	<p>Deferred with final opportunity for the submission of following documents:</p> <ul style="list-style-type: none"> • Prescribed form 5 is required. • Brand name to be changed and alternate name to be provided by the principal manufacturer on its official letter head. • Free sale certificate issued by the regulatory body in the country of origin, is required. • GMP certificate issued by the regulatory body in the country of origin is required. • Testing specifications of raw materials and finished product is required. • Long term and accelerated stability studies data is required according to conditions of Zone IV A. • COA of raw materials and Finished product is required. • Agency agreement is required.
308.	Multi Toxin Binder Oral Solution	<p>Deferred with final opportunity for the submission of following documents:</p> <ul style="list-style-type: none"> • Prescribed form 5 is required. • Brand name to be changed and alternate name to be provided by the principal manufacturer on its official letter head.

S.No (1)	Brand name (2)	Decision (3)
		<ul style="list-style-type: none"> • Free sale certificate issued by the regulatory body in the country of origin, is required. • GMP certificate issued by the regulatory body in the country of origin is required. • Testing specifications of raw materials and finished product is required. • Long term and accelerated stability studies data is required according to conditions of Zone IV A. • COA of raw materials and Finished product is required. • Agency agreement is required.
309.	Multi Protector Oral Solution	<p>Deferred with final opportunity for the submission of following documents:</p> <ul style="list-style-type: none"> • Prescribed form 5 is required. • Brand name to be changed and alternate name to be provided by the principal manufacturer on its official letter head. • Free sale certificate issued by the regulatory body in the country of origin, is required. • GMP certificate issued by the regulatory body in the country of origin is required. • Testing specifications of raw materials and finished product is required. • Long term and accelerated stability studies data is required according to conditions of Zone IV A. • COA of raw materials and Finished product is required. • Agency agreement is required.
310.	Multi ND Saver Oral Solution	<p>Deferred with final opportunity for the submission of following documents:</p> <ul style="list-style-type: none"> • Prescribed form 5 is required. • Brand name to be changed and alternate name to be provided by the principal manufacturer on its official letter head. • Free sale certificate issued by the regulatory body in the country of origin, is required. • GMP certificate issued by the regulatory body in the country of origin is required. • Testing specifications of raw materials and finished product is required. • Long term and accelerated stability studies data is required according to conditions of Zone IV A. • COA of raw materials and Finished product is required. • Agency agreement is required.
311.	Multi E.Coli Saver Oral Solution	<p>Deferred with final opportunity for the submission of following documents:</p> <ul style="list-style-type: none"> • Prescribed form 5 is required. • Brand name to be changed and alternate name to be provided by the principal manufacturer on its official letter head. • Free sale certificate issued by the regulatory body in the country of origin, is required. • GMP certificate issued by the regulatory body in the country of origin is required. • Testing specifications of raw materials and finished product is required. • Long term and accelerated stability studies data is required according to conditions of Zone IV A. • COA of raw materials and Finished product is required. • Agency agreement is required.
312.	Multi Enteritis Oral Solution	<p>Deferred with final opportunity for the submission of following documents:</p> <ul style="list-style-type: none"> • Prescribed form 5 is required. • Brand name to be changed and alternate name to be provided by the principal manufacturer on its official letter head.

S.No (1)	Brand name (2)	Decision (3)
		<ul style="list-style-type: none"> • Free sale certificate issued by the regulatory body in the country of origin, is required. • GMP certificate issued by the regulatory body in the country of origin is required. • Testing specifications of raw materials and finished product is required. • Long term and accelerated stability studies data is required according to conditions of Zone IV A. • COA of raw materials and Finished product is required. • Agency agreement is required.
313.	Multi Virus Saver Powder	<p>Deferred with final opportunity for the submission of following documents:</p> <ul style="list-style-type: none"> • Prescribed form 5 is required. • Brand name to be changed and alternate name to be provided by the principal manufacturer on its official letter head. • Free sale certificate issued by the regulatory body in the country of origin, is required. • GMP certificate issued by the regulatory body in the country of origin is required. • Testing specifications of raw materials and finished product is required. • Long term and accelerated stability studies data is required according to conditions of Zone IV A. • COA of raw materials and Finished product is required. • Agency agreement is required.
M/s Hospira Pharma (Pvt) Ltd., 1st Floor, Gradee Trust Building, Napier Road, Lahore agent of M/s Weihai Baihe Biology Technological Co. Ltd, Chengda Road, the Swan Lake Economic and Technical Development Zone, Rongcheng City, Weihai City, Shandong, P.R. China (E. No. 00838)		
314.	BoneLock Softgel	<p>Deferred with final opportunity for the provision of following documents:</p> <ul style="list-style-type: none"> • Long term stability studies data is required according to conditions of Zone IV A. • Free sale certificate issued by the regulatory body in the country of origin is required. • COA of finished product is required. • GMP Certificate/last inspection report and Agency agreement is required. • Evidence of fee is required.
315.	VD Softgel	<p>Deferred with final opportunity for the provision of following documents:</p> <ul style="list-style-type: none"> • Long term stability studies data is required according to conditions of Zone IV A. • Free sale certificate issued by the regulatory body in the country of origin is required. • COA of finished product is required. • GMP Certificate/last inspection report and Agency agreement is required. • Evidence of fee is required.
M/s Bismillah Traders, located at the address Quanchi More Lahore Road, Sargodha agent of M/s Akron S.r.l, Via Bernini, 17-20094 Corsico (MI), Italy (E.No. 00927)		
316.	Pollovet Extra E+Sel 20%	<p>Deferred with final opportunity for the provision of following documents:</p> <ul style="list-style-type: none"> • Firm is required to submit application on form 5 alongwith prescribed fee except of COA of finished product.
317.	Pollo Animomix	<p>Deferred with final opportunity for the provision of following documents:</p> <ul style="list-style-type: none"> • Firm is required to submit application on form 5 alongwith prescribed fee except of COA of finished product.
318.	Puliren Pollo	<p>Deferred with final opportunity for the provision of following documents:</p>

S.No	Brand name	Decision
(1)	(2)	(3)
		<ul style="list-style-type: none"> Firm is required to submit application on form 5 alongwith prescribed fee except of COA of finished product.
319.	Pollo Minaphos	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> Firm is required to submit application on form 5 alongwith prescribed fee except of COA of finished product.
320.	Pollovet K W/S 200	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> Firm is required to submit application on form 5 alongwith prescribed fee except of COA of finished product.
321.	Pollo ADEK-C	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> Firm is required to submit application on form 5 alongwith prescribed fee except of COA of finished product.
322.	Pollotox Bind	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> Firm is required to submit application on form 5 alongwith prescribed fee except of COA of finished product. Role of Bentonite (Toxcin Binder) as health product and Alternative medicine is required.
323.	Pollo ADEK	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> Firm is required to submit application on form 5 alongwith prescribed fee except of COA of finished product.
324.	Pollo Super Tonic	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> Firm is required to submit application on form 5 alongwith prescribed fee except of COA of finished product. Silymarin is included in the list of common molecule.
325.	Dina Adekc	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> Firm is required to submit application on form 5 alongwith prescribed fee except of COA of finished product.
M/s Bismillah Traders, Quanchi More Lahore Road, Sargodha, agent of M/s Thien Quan Joint Stock Company, Lot 17F2-No.5, Street – Tra Noc Industrial Zone I, Binh Thuy Dist- Can Tho City-Vietnam (E. No. 00449)		
326.	DINA Gold	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> Long term and accelerated stability studies data is required according to conditions of Zone IV A. Free sale certificate issued by the regulatory body in the country of origin is required. Agency agreement is required.
327.	Mycrozal	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> Ammonium Chloride is included in the list of common molecule. Long term and accelerated stability studies data is required according to conditions of Zone IV A. Free sale certificate issued by the regulatory body in the country of origin is required. Agency agreement is required.
M/s. Sind Medical Stores, 13-B, Block 6, PECHS, Shahrah-e-Faisal, Karachi-Pakistan agent of M/s Nutriset, Hameau du Bois ricard – CS 80035, 76770 Malaunay, FRANCE (E. No. 00200)		
328.	F-100 Therapeutic Milk	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> Evidence stating hilal source of Fats and proteins is required. Brand name to be changed and alternative brand name to be provided by the principal manufacturer/agent on its official letter head.

S.No	Brand name	Decision
(1)	(2)	(3)
		<ul style="list-style-type: none"> Documents reveal (last inspection report conducted by third party) that M/s Inigny Ste Mere, France is a contract manufacturer towards M/s Nutriset Malanuay, France since 2016. In this regards clarification is required to establish relationship between 2 (two) above mentioned firms, as form 6 does not hold any such information. Clarification is also required who is principal manufacturer and distributor/agent in country of origin (France). Free sale certificate stating name of principal manufacturer and marketing rights holder (if any) issued by the regulatory body in the country of origin. Long term and accelerated stability studies data is required according to conditions of Zone IV A.
329.	ReSoMal	<p>Deferred with final opportunity for the provision of following documents:</p> <ul style="list-style-type: none"> Evidence stating hilal source of Fats and proteins is required. Brand name to be changed and alternative brand name to be provided by the principal manufacturer/agent on its official letter head. Documents reveal (last inspection report conducted by third party) that M/s Inigny Ste Mere, France is a contract manufacturer towards M/s Nutriset Malanuay, France since 2016. In this regards clarification is required to establish relationship between 2 (two) above mentioned firms, as form 6 does not hold any such information. Clarification is also required who is principal manufacturer and distributor/agent in country of origin (France). Free sale certificate stating name of principal manufacturer and marketing rights holder (if any) issued by the regulatory body in the country of origin. Long term and accelerated stability studies data is required according to conditions of Zone IV A.
330.	F-75 Therapeutic Milk	<p>Deferred with final opportunity for the provision of following documents:</p> <ul style="list-style-type: none"> Evidence stating hilal source of Fats and proteins is required. Brand name to be changed and alternative brand name to be provided by the principal manufacturer/agent on its official letter head. Documents reveal (last inspection report conducted by third party) that M/s Inigny Ste Mere, France is a contract manufacturer towards M/s Nutriset Malanuay, France since 2016. In this regards clarification is required to establish relationship between 2 (two) above mentioned firms, as form 6 does not hold any such information. Clarification is also required who is principal manufacturer and distributor/agent in country of origin (France). Free sale certificate stating name of principal manufacturer and marketing rights holder (if any) issued by the regulatory body in the country of origin. Long term and accelerated stability studies data is required according to conditions of Zone IV A.
M/s A.S.M. Pharma, 47-Basement, Al-Miraj Arcade, Chouburji, Lahore agent of M/s Methodo Chemical s.r.l., via del lavoro 9, 46020 Marcara, Italy (E. No. 00644)		
331.	Methodo AMO	<p>Deferred with final opportunity for for the provision of following documents:</p> <ul style="list-style-type: none"> Long term (stating physical, chemical and microbial testing perimeter to be conducted every 3 months in first year, every 6 months in 2nd year and every year thereafter) and accelerated stability studies (Time points to be at 0 months, 3 months and 6 month) data is required according to conditions of Zone IV A.

S.No	Brand name	Decision
(1)	(2)	(3)
		<ul style="list-style-type: none"> • GMP issued by the regulatory body in the country of origin is required. • Agency agreement is required. • COA of finished product is required. • Fee challan is not endorsed by the concern department of DRAP.
332.	Enzy Pro	<p>Deferred with final opportunity for for the provision of following documents:</p> <ul style="list-style-type: none"> • Long term (stating physical, chemical and microbial testing permieter to be conducted every 3 months in first year, every 6 months in 2nd year and every year thereafter) and accelerated stability studies (Time points to be at 0 months, 3 months and 6 month) data is required according to conditions of Zone IV A. • GMP issued by the regulatory body in the country of origin is required. • Agency agreement is required. • COA of finished product is required. • Fee challan is not endorsed by the concern department of DRAP.
333.	Methodo C MD3	<p>Deferred with final opportunity for for the provision of following documents:</p> <ul style="list-style-type: none"> • Long term (stating physical, chemical and microbial testing permieter to be conducted every 3 months in first year, every 6 months in 2nd year and every year thereafter) and accelerated stability studies (Time points to be at 0 months, 3 months and 6 month) data is required according to conditions of Zone IV A. • GMP issued by the regulatory body in the country of origin is required. • Agency agreement is required. • COA of finished product is required. • Fee challan is not endorsed by the concern department of DRAP.
334.	P-Fenol	<p>Deferred with final opportunity for for the provision of following documents:</p> <ul style="list-style-type: none"> • Long term (stating physical, chemical and microbial testing permieter to be conducted every 3 months in first year, every 6 months in 2nd year and every year thereafter) and accelerated stability studies (Time points to be at 0 months, 3 months and 6 month) data is required according to conditions of Zone IV A. • GMP issued by the regulatory body in the country of origin is required. • Agency agreement is required. • COA of finished product is required. • Fee challan is not endorsed by the concern department of DRAP.
M/s Hassan Brothers, House No.P-318, Street No.6, Mohallah Fatehabad Sharqi, Satiana Road, Faisalabad-Pakistan agent of M/s Samyang Anipharm Co., Ltd., 35, Songseon-ro 265beon-gil, Pocheon-si, Gyeonggi-do, Korea (Veterinary) (E. No. 00605)		
335.	TOXO-BOND P	<p>Deferred with final opportunity for the provision of following documents:</p> <ul style="list-style-type: none"> • Free sale certificate issued by the regulatory body in the country of origin is required. • COA of Finished product is required. • Evidence of fee is required. • Long term and accelerated stability studies data is required according to conditions of Zone IV A.
M/s. DMG, Diversified Marketing Group, 245, Ground Floor, Saidpur Road, Scheme No. 1, Rawalpindi-Pakistan agent of M/s. Specialty Biotech Co., Ltd., Free Zone Amata Nakom Industrial Park 700/137 Moo 5, Klongtumroo, Muang, Chonburi 20000, THAILAND (Veterinary use) (E. No. 00133)		
336.	Nanosorb	<p>Deferred with final opportunity for the provision of following documents:</p> <ul style="list-style-type: none"> • Form 5 duly stamped and signed is not provided. • Justification about rationalityof formulation is required, since it contains almost pure yeast cell. • Free sale certificate, GMP (issued by the regulatory body in the country of origin) are required.

S.No	Brand name	Decision
(1)	(2)	(3)
		<ul style="list-style-type: none"> • Agency agreement is required. • Long term and accelerated stability studies data is required according to conditions of Zone IV A.
337.	Proyeast	<p>Deferred with final opportunity for the provision of following documents:</p> <ul style="list-style-type: none"> • Form 5 duly stamped and signed is not provided. • Justification about rationality of formulation is required, since it contains almost pure yeast cell. • Free sale certificate, GMP (issued by the regulatory body in the country of origin) are required. • Agency agreement is required. • Long term and accelerated stability studies data is required according to conditions of Zone IV A.
M/s. DMG, Diversified Marketing Group, 245, Ground Floor, Saidpur Road, Scheme No. 1, Rawalpindi-Pakistan agent of M/s. Tanin Solvenia, D.D. Hermanova Cesta, 1 8290 Sevnica-Slovenia, SLOVENIA (Veterinary use) (E. No. 00132)		
338.	Farmatan SSC	<p>Deferred with final opportunity for the provision of following documents:</p> <ul style="list-style-type: none"> • Form 5 duly stamped and signed is not provided. • Free sale certificate, GMP (issued by the regulatory body in the country of origin) are required. • Agency agreement is required. • Long term and accelerated stability studies data is required according to conditions of Zone IV A.
339.	Farmatan BCO	<p>Deferred with final opportunity for the provision of following documents:</p> <ul style="list-style-type: none"> • Form 5 duly stamped and signed is not provided. • Free sale certificate, GMP (issued by the regulatory body in the country of origin) are required. • Agency agreement is required. • Long term and accelerated stability studies data is required according to conditions of Zone IV A.
M/s Binsadiq International, 307/A, Canal View Housing Society Lahore-53700-Pakistan agent M/s Ballinskelligs Veterinary Products Ltd., (BVP Animal Care), Ballinskelligs, Co. Kerry, Ireland (E. No. 00538)		
340.	Bovitrace Extra	<p>Deferred with final opportunity for the provision of following documents:</p> <ul style="list-style-type: none"> • Form 5 is required. • Dosage form, strength of active ingredient, Pack size needs to be clarified. • Long term and accelerated stability studies data is required according to conditions of Zone IV A.
M/s Binsadiq International, 307/A Canal View Society, Lahore-53700-Pakistan agent of M/s Pancosma Group, Voie-des-Traz 6, 1218 Le Grand-Saconnex-Geneva, Switzerland [Principal Manufacturer: M/s Sermix, 3, rue Barthelemy Thimonnier 01000 Bourg-En-Bresse, France] (E. No. 00563)		
341.	B-Traxim 2C Cu-240 Powder	<p>Deferred with the final opportunity for the provision of following documents:</p> <ul style="list-style-type: none"> • Form 5 is required. • Copy of Free sale certificate reveals that said product is manufactured by M/s Pancosma S.A, Switzerland however according to Form 6 information, the principal manufacturer is M/s Sermix, 3, rue Barthelemy Thimonnier 01000 Bourg-En-Bresse, France while M/s Pancosma, Switzerland is an agent, needs clarification in this regards. • Original Free sale certificate is required. • Evidence stating relationship of M/s Pancosma, Switzerland and M/s Sermix, France is required. • Dosage form, strength of active ingredient, Pack size needs to be clarified. • Clarification is required who is principal manufacturer of said product and who has market authorization rights. • Long term and accelerated stability studies data is required according to conditions of Zone IV A.

S.No (1)	Brand name (2)	Decision (3)
342.	Covotek 575	<p>Deferred with the final opportunity for the provision of following documents:</p> <ul style="list-style-type: none"> Form 5 is required. Copy of Free sale certificate reveals that said product is manufactured by M/s Pancosma S.A, Switzerland however according to Form 6 information, the principal manufacturer is M/s Sermix, 3, rue Barthelemy Thimonnier 01000 Bourg-En-Bresse, France while M/s Pancosma, Switzerland is an agent, needs clarification in this regards. Original Free sale certificate is required. Evidence stating relationship of M/s Pancosma, Switzerland and M/s Sermix, France is required. Dosage form, strength of active ingredient, Pack size needs to be clarified. Clarification is required who is principal manufacturer of said product and who has market authorization rights. Long term and accelerated stability studies data is required according to conditions of Zone IV A.
343.	B-Traxim 2C Mn-220	<p>Deferred with the final opportunity for the provision of following documents:</p> <ul style="list-style-type: none"> Form 5 is required. Copy of Free sale certificate reveals that said product is manufactured by M/s Pancosma S.A, Switzerland however according to Form 6 information, the principal manufacturer is M/s Sermix, 3, rue Barthelemy Thimonnier 01000 Bourg-En-Bresse, France while M/s Pancosma, Switzerland is an agent, needs clarification in this regards. Original Free sale certificate is required. Evidence stating relationship of M/s Pancosma, Switzerland and M/s Sermix, France is required. Dosage form, strength of active ingredient, Pack size needs to be clarified. Clarification is required who is principal manufacturer of said product and who has market authorization rights. Long term and accelerated stability studies data is required according to conditions of Zone IV A.
344.	B-Traxim 2C Fe-220	<p>Deferred with the final opportunity for the provision of following documents:</p> <ul style="list-style-type: none"> Form 5 is required. Copy of Free sale certificate reveals that said product is manufactured by M/s Pancosma S.A, Switzerland however according to Form 6 information, the principal manufacturer is M/s Sermix, 3, rue Barthelemy Thimonnier 01000 Bourg-En-Bresse, France while M/s Pancosma, Switzerland is an agent, needs clarification in this regards. Original Free sale certificate is required. Evidence stating relationship of M/s Pancosma, Switzerland and M/s Sermix, France is required. Dosage form, strength of active ingredient, Pack size needs to be clarified. Clarification is required who is principal manufacturer of said product and who has market authorization rights. Long term and accelerated stability studies data is required according to conditions of Zone IV A.
345.	Sucram 55 Hydro	<p>Deferred with the final opportunity for the provision of following documents:</p> <ul style="list-style-type: none"> Form 5 is required. Copy of Free sale certificate reveals that said product is manufactured by M/s Pancosma S.A, Switzerland however according to Form 6 information, the principal manufacturer is M/s Sermix, 3, rue Barthelemy Thimonnier 01000 Bourg-En-Bresse, France while

S.No (1)	Brand name (2)	Decision (3)
		<p>M/s Pancosma, Switzerland is an agent, needs clarification in this regards.</p> <ul style="list-style-type: none"> • Original Free sale certificate is required. • Evidence stating relationship of M/s Pancosma, Switzerland and M/s Sermix, France is required. • Dosage form, strength of active ingredient, Pack size needs to be clarified. • Clarification is required who is principal manufacturer of said product and who has market authorization rights. • Long term and accelerated stability studies data is required according to conditions of Zone IV A.
346.	B-Traxim Pro4	<p>Deferred with the final opportunity for the provision of following documents:</p> <ul style="list-style-type: none"> • Form 5 is required. • Copy of Free sale certificate reveals that said product is manufactured by M/s Pancosma S.A, Switzerland however according to Form 6 information, the principal manufacturer is M/s Sermix, 3, rue Barthelemy Thimonnier 01000 Bourg-En-Bresse, France while M/s Pancosma, Switzerland is an agent, needs clarification in this regards. • Original Free sale certificate is required. • Evidence stating relationship of M/s Pancosma, Switzerland and M/s Sermix, France is required. • Dosage form, strength of active ingredient, Pack size needs to be clarified. • Clarification is required who is principal manufacturer of said product and who has market authorization rights. • Long term and accelerated stability studies data is required according to conditions of Zone IV A.
347.	Xtract Nature, code X60-6986	<p>Deferred with the final opportunity for the provision of following documents:</p> <ul style="list-style-type: none"> • Form 5 is required. • Copy of Free sale certificate reveals that said product is manufactured by M/s Pancosma S.A, Switzerland however according to Form 6 information, the principal manufacturer is M/s Sermix, 3, rue Barthelemy Thimonnier 01000 Bourg-En-Bresse, France while M/s Pancosma, Switzerland is an agent, needs clarification in this regards. • Original Free sale certificate is required. • Evidence stating relationship of M/s Pancosma, Switzerland and M/s Sermix, France is required. • Dosage form, strength of active ingredient, Pack size needs to be clarified. • Clarification is required who is principal manufacturer of said product and who has market authorization rights. • Long term and accelerated stability studies data is required according to conditions of Zone IV A.
348.	Xtract, Code 6930	<p>Deferred with the final opportunity for the provision of following documents:</p> <ul style="list-style-type: none"> • Form 5 is required. • Copy of Free sale certificate reveals that said product is manufactured by M/s Pancosma S.A, Switzerland however according to Form 6 information, the principal manufacturer is M/s Sermix, 3, rue Barthelemy Thimonnier 01000 Bourg-En-Bresse, France while M/s Pancosma, Switzerland is an agent, needs clarification in this regards. • Original Free sale certificate is required. • Evidence stating relationship of M/s Pancosma, Switzerland and M/s Sermix, France is required. • Dosage form, strength of active ingredient, Pack size needs to be clarified.

S.No (1)	Brand name (2)	Decision (3)
		<ul style="list-style-type: none"> • Clarification is required who is principal manufacturer of said product and who has market authorization rights. • Long term and accelerated stability studies data is required according to conditions of Zone IV A.
349.	B-Traxin Pro2	<p>Deferred with the final opportunity for the provision of following documents:</p> <ul style="list-style-type: none"> • Form 5 is required. • Copy of Free sale certificate reveals that said product is manufactured by M/s Pancosma S.A, Switzerland however according to Form 6 information, the principal manufacturer is M/s Sermix, 3, rue Barthelemy Thimonnier 01000 Bourg-En-Bresse, France while M/s Pancosma, Switzerland is an agent, needs clarification in this regards. • Original Free sale certificate is required. • Evidence stating relationship of M/s Pancosma, Switzerland and M/s Sermix, France is required. • Dosage form, strength of active ingredient, Pack size needs to be clarified. • Clarification is required who is principal manufacturer of said product and who has market authorization rights. • Long term and accelerated stability studies data is required according to conditions of Zone IV A.
350.	B-Traxim 2C Zin-260	<p>Deferred with the final opportunity for the provision of following documents:</p> <ul style="list-style-type: none"> • Form 5 is required. • Copy of Free sale certificate reveals that said product is manufactured by M/s Pancosma S.A, Switzerland however according to Form 6 information, the principal manufacturer is M/s Sermix, 3, rue Barthelemy Thimonnier 01000 Bourg-En-Bresse, France while M/s Pancosma, Switzerland is an agent, needs clarification in this regards. • Original Free sale certificate is required. • Evidence stating relationship of M/s Pancosma, Switzerland and M/s Sermix, France is required. • Dosage form, strength of active ingredient, Pack size needs to be clarified. • Clarification is required who is principal manufacturer of said product and who has market authorization rights. • Long term and accelerated stability studies data is required according to conditions of Zone IV A.
M/s SZ International, located at the address Office No. 504 Beamount Plaza Beomount Karachi agent of M/s Phileo-Divison of S.I.Leasffre, 137 rue Gabriel peri 59700 Marq-en-Baroeul, France (E. No. 00761)		
351.	Safmannan Powder	<p>Deferred with final opportunity for the provision of following documents:</p> <ul style="list-style-type: none"> • Formulation given on form 5 and master formula is entirely different from each other, needs clarification. • Long term and accelerated stability studies data is required according to conditions of Zone IV A. • COA of Finished product and raw material is required. • Letter on the subject “free sales certificate for the export in the non-EU members states” does not depicted name of manufacturer i.e. M/s Phileo-Division of S.I.Leasffre, France rather reveals the following names: • <i>Name and address of manufacturing site Biospringer 6 Rue De Saint Nazaire – 67100 Strasbourg- France</i> • <i>And exported by SOciete Industrielle Leasaffre- 137rue Gabriel Peri – BP3029 – 59703 Marcq-Baroeul-France</i> • Needs clarification in this regards. Furthermore, the said document does not bear any signature of representative of embassy/consulate of Pakistan based in France.

S.No (1)	Brand name (2)	Decision (3)
		<ul style="list-style-type: none"> Evidence stating principal manufacturer and/or marketing authorization holder of said product is required.
352.	Actisaf Sc 47 Powder	<p>Deferred with final opportunity for the provision of following documents:</p> <ul style="list-style-type: none"> Formulation given on form 5 and master formula is entirely different from each other, needs clarification. Long term and accelerated stability studies data is required according to conditions of Zone IV A. COA of Finished product and raw material is required. Letter on the subject "free sales certificate for the export in the non-EU members states" does not depicted name of manufacturer i.e. M/s Phileo-Division of S.I.Leasffre, France rather reveals the following names: <ul style="list-style-type: none"> Name and address of manufacturing site Biospringer 6 Rue De Saint Nazaire – 67100 Strasbourg- France And exported by SOciete Industrielle Leasaffre- 137rue Gabriel Peri – BP3029 – 59703 Marcq-Baroeul-France Needs clarification in this regards. Furthermore, the said document does not bear any signature of representative of embassy/consulate of Pakistan based in France. Evidence stating principal manufacturer and/or marketing authorization holder of said product is required.
M/s SZ International, located at the address Office No. 504 Beamount Plaza Beamount Karachi agent of M/s Amlan International, 410 N. Michigan Ave. Suite 400, Chicago, Illinois, 60611 U.S.A. (Principal Manufacturer M/s M&M Milling, Incorporated, 1056 Fender Trail NE, Brookhaven MS 39601 USA) (E. No. 00827)		
353.	Varium	<p>Deferred with final opportunity for the provision of following documents:</p> <ul style="list-style-type: none"> Justification of role of Bentonite (Toxin binder) under health product and alternative medicine is required. Long term and accelerated stability studies data is required according to conditions of Zone IV A. Free sales certificate issued by Department of agriculture and commerce, State of Mississippi, USA reveals that Amlan International a division of Oil-Dri corporation of America – M&M Milling located at 1056 Fender Trail NE, Brookhaven MS 39601 USA provides different information about principal manufacturer and/or agent as compared to given on Form 6, needs clarification in this regards. Last inspection report and GMP certificate issued by the regulatory body in the country of origin is required.
M/s Hinucon, 12/1 Sector 15, Korangi Industrial Area, Karachi-Pakistan agent of M/s HC Clover Prdouctos Y Servicios S.L. C/ Alicante, 8-10, Arganda del Rey, 28500 Madrid Spain (E. No. 00606)		
354.	Pumro Softgel Capsule	<p>Deferred with final opportunity for the provision of following documents:</p> <ul style="list-style-type: none"> GMP certificate issued by the regulatory body in the country of origin is required. Long term and accelerated stability studies data is required according to conditions of Zone IV A. Free sale certificate does not depict free availability of Pumro softgel capsule in the country of origin.
355.	HANA Softgel Capsule	<p>Deferred with final opportunity for the provision of following documents:</p> <ul style="list-style-type: none"> GMP certificate issued by the regulatory body in the country of origin is required. Long term and accelerated stability studies data is required according to conditions of Zone IV A. Free sale certificate does not depict free availability of Pumro softgel capsule in the country of origin.
356.	Hilvot Softgel Capsule	<p>Deferred with final opportunity for the provision of following documents:</p>

S.No	Brand name	Decision
(1)	(2)	(3)
		<ul style="list-style-type: none"> • GMP certificate issued by the regulatory body in the country of origin is required. • Long term and accelerated stability studies data is required according to conditions of Zone IV A. • Free sale certificate does not depict free availability of Pumro softgel capsule in the country of origin.
357.	Femro Softgel Capsule	<p>Deferred with final opportunity for the provision of following documents:</p> <ul style="list-style-type: none"> • GMP certificate issued by the regulatory body in the country of origin is required. • Long term and accelerated stability studies data is required according to conditions of Zone IV A. • Free sale certificate does not depict free availability of Pumro softgel capsule in the country of origin.
M/s Hinucon, 12/1 Sector 15, Korangi Industrial Area, Karachi-Pakistan agent of M/s Ana Bio Research & Development Co., JSC, SO 22, Lot 7, LDT Van Khe, Ha Dong, Hanoi, Vietnam (E. No. 00607)		
358.	Endiar Oral Suspension	<p>Deferred with final opportunity for the provision of following documents:</p> <ul style="list-style-type: none"> • Free sale certificate is not issued by the concerned regulatory body in country of Origin. • GMP certificate issued by the regulatory body in the country of origin is required. • Long term and accelerated stability studies data is required according to conditions of Zone IV A.
M/s Orient		
Traders International, CM-10, Block-A, Kazimabad, Model Colony, Karachi-Pakistan agent of M/s Laboratories Biove, 3 Rue De Lorraine, 62510 Arques, France (00523)		
359.	Cid 2000	EEC was apprised that Division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the Division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of Division of Health & OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
M/s Aman Traders, 11/1 D, People Colony No. 1, Faisalabad agent of M/s PEKANA Naturheilmittel GmbH Raiffeisenstrasse 15, 88353 Kisslegg, Germany (E. No. 0030)		
360.	PK 61 Otidolo	<p>Deferred with final opportunity for the provision of following documents:</p> <ul style="list-style-type: none"> • Break up of Fee is required. • Long term and accelerated stability studies data is required according to conditions of Zone IV A. • Firm submitted CoPP issued by Federal office for Security Health Care Vien, Austria and counter signed by Pakistan embassy based at Vienna, Austria, in this regard it is submitted that CoPP/free sale certificate attested by concerned regulatory authority in country of origin i.e. Germany as the principal manufacturer is present in later country is required. • Belladonna D2 is required not to be dispensed owing to adverse effect, clarification is sought about use of such potency of Belladonna in the formulation without causing adverse effect.
M/s J & J's Pharmaceuticals, upper floor 85/G3 Wapda ECHS (WAPDA Town), Lahore-Pakistan agent of M/s Super's Diana, S.L., Ctra, C-17, Km 17, Parets del Valles, 08150 Barcelona (E. No. 00473)		
361.	Supersan Soluble	<p>Deferred with the final opportunity for the provision of following documents:</p> <ul style="list-style-type: none"> • Pack size is required. • COA of Finished product is required.
362.	Citrus Oral Solution	EEC was apprised that Division undertook a big task of company wise arrangement of applications in various designated racks. Since

S.No	Brand name	Decision
(1)	(2)	(3)
		computerization of record of submitted applications and subsequent preparation of their FIFO list, the Division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of Division of Health & OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
363.	Super E20% +Sel Oral Solution	EEC was apprised that Division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the Division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of Division of Health & OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
364.	Osmodian Oral Rehydration Powder	EEC was apprised that Division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the Division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of Division of Health & OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
365.	Super Adeck Oral Solution	EEC was apprised that Division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the Division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of Division of Health & OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
366.	Liver Tonic	EEC was apprised that Division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the Division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of Division of Health & OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
M/s Pak Medicine Corner, 1 & 1A Hilal-e-Ahmed Building, B.B Block, Dabgari Garderns, Peshawar Cantt agent of M/s Principle Healthcare International Ltd, Airedale Business Centre, Millennium Road, Skipton, North yarkshire BD23 2TZ, United Kingdom (E. No. 0046)		
367.	Womens Health Tablet	EEC was apprised that Division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the Division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of Division of Health & OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.

S.No (1)	Brand name (2)	Decision (3)
368.	Pregnancy Tablet	EEC was apprised that Division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the Division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of Division of Health & OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
369.	Amco Capsule	EEC was apprised that Division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the Division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of Division of Health & OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
370.	Men'S Health Tablet	EEC was apprised that Division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the Division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of Division of Health & OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
371.	Multivit & Iron Tablet	EEC was apprised that Division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the Division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of Division of Health & OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
372.	Multivitamin & Minerals Tablet	EEC was apprised that Division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the Division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of Division of Health & OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
373.	Bone Health Tablet	EEC was apprised that Division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the Division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of Division of Health & OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
M/s. Sigma Pharma International, 46-E/3, Block-6, PECHS, Karachi agent of M/s. NBTY Inc. 2100 Smithtown Avenue, Ronkonkoma, New York, USA (E. No. 00337)		

S.No (1)	Brand name (2)	Decision (3)
374.	Boncal Tablet	EEC was apprised that Division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the Division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of Division of Health & OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
375.	NB Mini Fish Oil 1290mg Softgel	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> • Long term and accelerated stability studies data is required according to conditions of Zone IV A. • COA of finished product stating chemical assay of active ingredients is required. • Free sale certificate is not provided.
376.	NB Fish Oil 1200mg Plus 360mg of Omega-3	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> • Long term and accelerated stability studies data is required according to conditions of Zone IV A. • COA of finished product stating chemical assay of active ingredients is required. • Free sale certificate is not provided.
377.	Super Advanced Mass Gainer Chocolate	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> • Long term and accelerated stability studies data is required according to conditions of Zone IV A. • COA of finished product stating chemical assay of active ingredients is required. • Free sale certificate is not provided.
378.	Radiant Skin Softgel	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> • Long term and accelerated stability studies data is required according to conditions of Zone IV A. • COA of finished product stating chemical assay of active ingredients is required. • Free sale certificate is not provided. • Testing specification of Cramosides (Wheat seed oil) is required. •
379.	Optimal Solution Complete Menopause Support Complex Tablet	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> • Long term and accelerated stability studies data is required according to conditions of Zone IV A. • Brand name needs to be changed. • Melatonin is included in the list of common molecule. • COA of finished product stating chemical assay of active ingredients is required. • Free sale certificate is not provided.
380.	Peppermint Oil 50mg Softgel	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> • Long term and accelerated stability studies data is required according to conditions of Zone IV A.. • COA of finished product stating chemical assay of active ingredients is required.

S.No	Brand name	Decision
(1)	(2)	(3)
		<ul style="list-style-type: none"> Free sale certificate is not provided.
381.	Met-Rx L-Carnitine 1000mg Caplet	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> Long term and accelerated stability studies data is required according to conditions of Zone IV A.. COA of finished product stating chemical assay of active ingredients is required. Free sale certificate is not provided.
382.	Met-Rx Ultramysyn Whey Isolate Chocolate	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> Long term and accelerated stability studies data is required according to conditions of Zone IV A.. COA of finished product stating chemical assay of active ingredients is required.
383.	Met-Rx ZMA Capsules	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> Long term and accelerated stability studies data is required according to conditions of Zone IV A..
384.	Met Rx Creatine 4200mg Capsule	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> Long term and accelerated stability studies data is required according to conditions of Zone IV A.. Free sale certificate is not provided.
385.	Potassium Gluconate 900mg Caplets	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> Long term and accelerated stability studies data is required according to conditions of Zone IV A.. Free sale certificate is not provided.
386.	Body Fortress Super Advanced Isolate Protein Chocolate	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> Long term and accelerated stability studies data is required according to conditions of Zone IV A.. COA of finished product stating chemical assay of active ingredients is required.
387.	Met-Rx L-Glutamine Powder	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> Long term and accelerated stability studies data is required according to conditions of Zone IV A..
388.	NB B-2 100mg Tablet	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> Long term and accelerated stability studies data is required according to conditions of Zone IV A.. COA of finished product stating chemical assay of active ingredients is required. Free sale certificate is not provided. Evidence of fee is required.
389.	Met-Rx Ultramysyn Whey Protein Powder Chocolate	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> Long term and accelerated stability studies data is required according to conditions of Zone IV A.. COA of finished product stating chemical assay of active ingredients is required.

S.No (1)	Brand name (2)	Decision (3)
390.	Met-Rx Ultramysyn Whey Isolate Vanilla	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> • Evidence stating Hilal source of fat and protein. • Long term and accelerated stability studies data is required according to conditions of Zone IV A. .
391.	Flex-a-min Super Glucosamine 2000 Plus Caplets	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> • Long term and accelerated stability studies data is required according to conditions of Zone IV A. • Glucosamine and Hyaluronic are included in the list of common molecule. • COA of finished product stating chemical assay of active ingredients is required. • Free sale certificate is not provided. .
392.	Triple Strength + MSM Formula tablet	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> • Long term and accelerated stability studies data is required according to conditions of Zone IV A. • Evidence of fee is required. • Glucosamine and Hyaluronic are included in the list of common molecule. • COA of finished product stating chemical assay of active ingredients is required. • Free sale certificate is not provided. .
393.	NB Ginkgo Biloba 120mg Capsule	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> • Long term and accelerated stability studies data is required according to conditions of Zone IV A. • Duplication of file needs clarification. • COA of finished product stating chemical assay of active ingredients is required. • Free sale certificate is not provided.. .
394.	Digest HB Capsule	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> • Long term and accelerated stability studies data is required according to conditions of Zone IV A. • Free sale certificate is not provided.. .
395.	Aloe Vera Gel 5000mg Softgel	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> • Long term and accelerated stability studies data is required according to conditions of Zone IV A. • COA of finished product stating chemical assay of active ingredients is required. • Justification of use of Aloe vera for oral intake is required. • Free sale certificate is not provided. .
396.	Probiotic 10 Capsule	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> • Long term and accelerated stability studies data is required according to conditions of Zone IV A. • Testing specification and characterization of each probiotic is required. • COA of finished product stating chemical assay of active ingredients is required. • Free sale certificate is not provided. .
397.	Met-Rx BCAA 2200 Softgel	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> • Long term and accelerated stability studies data is required according to conditions of Zone IV A. .

S.No (1)	Brand name (2)	Decision (3)
		<ul style="list-style-type: none"> • COA of finished product stating chemical assay of active ingredients is required. • Free sale certificate is not provided.
398.	Garcinia Combogia & Coconut Oil Softgel	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> • Long term and accelerated stability studies data is required according to conditions of Zone IV A. • COA of finished product stating chemical assay of active ingredients is required.
399.	NB Turmeric 450mg capsule	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> • Long term and accelerated stability studies data is required according to conditions of Zone IV A.
400.	OBF Joint and Muscle Capsule	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> • Long term and accelerated stability studies data is required according to conditions of Zone IV A. • COA of finished product stating chemical assay of aBoswellia serrat and prunus cerasus is required. • Free sale certificate is not provided. •
401.	NB Healthy Hair Capsule	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> • Long term and accelerated stability studies data is required according to conditions of Zone IV A. • COA of finished product of NB Healthy Hair Capsule is required.
402.	NB Garlic 2000 mg Tablet	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> • Long term and accelerated stability studies data is required according to conditions of Zone IV A. • COA of finished product stating chemical assay of Garlic is required. • Free sale certificate is not provided.
403.	Co Q-10 100mg Plus L-carnitine Softgel	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> • Long term and accelerated stability studies data is required according to conditions of Zone IV A. • COA of finished product stating chemical assay of active ingredients is required.
404.	Fish Oil 1000 Plus Omega-3 Softgel	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> • Long term and accelerated stability studies data is required according to conditions of Zone IV A. • Free sale certificate is not provided.
405.	NB Sublingual Liquid B-Complex	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> • Long term and accelerated stability studies data is required according to conditions of Zone IV A. • Free sale certificate is not provided.
406.	NB Green Tea 315mg Capsule	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> • Long term and accelerated stability studies data is required according to conditions of Zone IV A. • Strength mentioned in brand name (315mg) does not co relate strength as given in formulation (630mg). • COA of finished product stating chemical assay of active ingredients is required. • Free sale certificate is not provided.

S.No	Brand name	Decision
(1)	(2)	(3)
407.	OBF One per Day Tablet	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> • Long term and accelerated stability studies data is required according to conditions of Zone IV A. • Glucosamine is included in the list of common molecule. • COA of finished product stating physical and chemical assay (vitamin D, Boswellia serrata).
408.	NB D3 400IU Tablet	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> • Long term and accelerated stability studies data is required according to conditions of Zone IV A. • Evidence of Fee is required.
409.	Optimal Solution Protein and Vitamin Shake Mix Vanilla Powder	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> • Long term and accelerated stability studies data is required according to conditions of Zone IV A. • Evidence stating hilal source of Fats and Protein.
410.	NB B6 100mg Tablet	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> • Evidence of fee is required. • Long term and accelerated stability studies data is required according to conditions of Zone IV A. • COA of finished product stating chemical assay of active ingredients is required. • Free sale certificate is not provided.
411.	Met-Rx Protein Plus Powder Chocolate	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> • Long term and accelerated stability studies data is required according to conditions of Zone IV A. • Role of use of cholesterol as an active ingredient is required. • COA of finished product stating chemical assay of active ingredients is required. • Free sale certificate is not provided.
412.	Met-Rx Protein Plus Powder Vanilla	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> • Long term and accelerated stability studies data is required according to conditions of Zone IV A.
413.	NB D3 2000IU Softgel	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> • Long term and accelerated stability studies data is required according to conditions of Zone IV A. • COA of finished product stating chemical assay of active ingredients is required.
414.	NB Saw Palmetto Capsule	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> • Long term and accelerated stability studies data is required according to conditions of Zone IV A. • COA of finished product stating chemical assay of Saw Palmetto is required.
415.	NB Ginkgo Biloba 120mg Capsule	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> • Long term and accelerated stability studies data is required according to conditions of Zone IV A. • COA of finished product stating chemical assay of Ginkgo Biloba is required • Free sale certificate is not provided.

S.No (1)	Brand name (2)	Decision (3)
416.	Apple Cider Vinegar 480mg Tablet	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> Long term and accelerated stability studies data is required according to conditions of Zone IV A. COA of finished product stating chemical assay of apple cider vinegar is required. Free sale certificate is not provided.
417.	NB Activate Charcoal Capsule	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> Long term and accelerated stability studies data is required according to conditions of Zone IV A. Activated Charcoal is included in the list of common molecule. COA of finished product stating chemical assay of activated charcoal is required. Free sale certificate is not provided.
418.	BF Super Advance Amino Blast Lemon Lime Powder	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> Long term and accelerated stability studies data is required according to conditions of Zone IV A. COA of Finished product stating chemical assay of active ingredients is required.
419.	Osteo Bi-Flex Herbal Formula with Turmerix 80 Vegetarian Capsule	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> Long term and accelerated stability studies data is required according to conditions of Zone IV A. COA of finished product stating chemical assay of active ingredients is required.
420.	Met-Rx Buttermilk High Protein Pancake Mix	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> Long term and accelerated stability studies data is required according to conditions of Zone IV A. Evidence stating hilal source of Fats and Protein. COA of finished product stating chemical assay of active ingredients is required.
421.	Body Fortress Super Advanced Isolate Protein Vanilla	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> Long term and accelerated stability studies data is required according to conditions of Zone IV A. COA of finished product stating chemical assay of active ingredients is required.
M/s Base6 Private Limited, Lahore		
422.	Basixtm	EEC was apprised that Division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the Division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of Division of Health & OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
423.	Nf Vitamin C Time Release	EEC was apprised that Division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the Division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EC appreciated the services of Division of Health & OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.

S.No (1)	Brand name (2)	Decision (3)
M/s Gestirn Health Care located at the address Flat No. 003 Chapal Apartments, Gulistan-e-Johar, Block 13, Karachi agent of M/s Moleac PTE., Ltd., Singapore (exporter), M/s Poli Medical Company Pte Ltd., 65 Sims Avenue No. 08-07 Yi Xiu Factory Building Singapore 387418 (Primary Manufacturer) (E. No. 00831)		
424.	NeuroAID II MLC 901 Capsule	Deferred with final opportunity for the provision of following deficiencies: The Composition of the product mentioned on the free sale certificate and form 5 are not identical, needs clarification in this regards.
M/s Ghazi Brothers located at the address Ghazi House, D-35, KDA Scheme No 1, Miran Muhammad Shah Road, Karachi-Pakistan agent of M/s Vitalac, 48, rue principale, 22160 Carnoet, France (E. No. 00745)		
425.	Glycoline Powder	Deferred for clarification and justification of formulation and role of ingredients:
M/s Ghazi Brothers, located at the address Ghazi House, D-35, KDA Scheme #1, Miran Muhammad Shah Road, Karachi-75350-Pakistan agent of M/s The Ballard Group, Inc. Bluegrass Dairy Food, Inc. 1117 Cleveland Avenue, Glasgow, Ky 42141, USA (E. No. 00665)		
426.	Salmate	Deferred with final opportunity for the provision of following documents: • Free sale certificate does not depict free availability of salmate in the country of origin.
M/s Ghazi Brothers, located at Ghazi House, D-35, KDA Scheme No.1, Miran Mohammad Shah Road, Karachi agent of M/s Yantai Jinhai Pharmaceutical Co., Ltd., located at Jilin Road, Qixia Economic Development Zone, Yantai, Shandong, China (E. No. 01001)		
427.	Avision	Deferred with final opportunity for provision of following documents: • Valid GMP certificate issued by the regulatory body in the country in origin is required. As the GMP
M/s Erber Biotech Pakistan (Pvt.) Ltd., Block A, Plot No. 31, Street No. 1, Eden Value Homes Multan Road, Lahore agent of M/s Biomim Singapore Pte Ltd., 2 Woodlands Sector 1 # 05-02, Woodlands Spectrum, Singapore (E. No. 01073)		
428.	Mycofix Select 3.0	Deferred for clarification and justification of formulation and role of clay as nutraceutical health product under SRO 412
M/s. Tarobina Corporation, 226 Ahmed Block, New Garden Town, Lahore-Pakistan agent of M/s. K.M.P Biotech Co., Ltd, No. 188/9 Village No. 2, Khalong Tamru Sub-district mueang Chon Buri District Chun Buri Province, Postal Code 20000., Thailand (Veterinary use) (E. No. 00131)		
429.	AroLief	Deferred with final opportunity for the provision of following documents: Deferred for following reasons: • Prescribed Form 5 is required. • GMP Compliant report of principal manufacturer is required. • Long term and accelerated stability studies data is required according to conditions of Zone IV A.
430.	Soelab Pass	EEC was apprised that Division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the Division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of Division of Health & OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
M/s Tabros Pharma (Pvt) Ltd, Essa House 32-1-C, Block 6, P.E.C.H.S., Karachi agent of M/s ANA Bio Stock Company, Lo 7, Lien Ke 22, KDT Van Khe, Ha Dong, Ha Noi, Viet Nam (E. No. 00100)		
431.	BC-4Bio Oral Suspension	Deferred with final opportunity for the provision of following documents: • Testing specification and characterization of Bacillus clausii is required. • Pack size mentioned on Form 5 (8 Drinkable flasks of 5ml) and Pack size on Stability studies data and product profile is 5ml ampoule plastic container, needs clarification. • Clarification is required either said product is sterilized or otherwise, if it is sterilized, sterility test report to be provided as a part of COA and long term and accelerated stability studies profile. • COA of raw material and finished product is required.

S.No	Brand name	Decision
(1)	(2)	(3)
		<ul style="list-style-type: none"> Free sale certificate issued by concerned regulatory body in the country origin is required.
M/s The Searle Company Limited, First Floor, N.I.C.L. Building Abbasi Shaheed Road, Karachi agent of M/s Meksmar, Ivedik Organize Sanayi Bolgesi Agac Isleri San. Sit. 1333. Cad. No.27 Yenimahalle-Ankara, Turkey (E. No. 0054)		
432.	Locket Lozenges (Lemon Flavored Lozenges with Ginger Vitamin C)	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> COA of finished product is required. Long term and accelerated stability studies data is required according to conditions of Zone IV A. Free sale certificate issued by concerned regulatory body in the country origin. GMP certificate and Last inspection report is required.
433.	Locket Lozenges (Lemon Flavored Lozenges with Honey)	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> COA of finished product is required. Long term and accelerated stability studies data is required according to conditions of Zone IV A. Free sale certificate issued by concerned regulatory body in the country origin. GMP certificate and Last inspection report is required.
M/s The Searle Company Limited, First Floor, N.I.C.L. Building, Abbasi Shaheed Road, Karachi-Pakistan agent M/s HOCHDORF Swiss Nutrition Ltd., Siedereistrasse 9, 6281 Hochdorf, Switzerland (E. No. 00486)		
434.	NI-Grow +	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> Signed and Stamped prescribed Form 5 is required. Long term and accelerated stability studies data is required according to conditions of Zone IV A. COA of finished product of Ni-Grow + is required. Details of Antioxidants been used in formulation, is required. Free sale certificate issued by concerned regulatory body in the country origin is required.
M/s The Searle Company Limited, First Floor, N.I.C.L. Building, Abbasi Shaheed Road, Karachi-Pakistan agent M/s Belourth S.A., Des Villas 3-4180- Hamoir, Belgium (E. No. 00740)		
435.	Nurtulac Wheat-Milk-5 Fruits	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> Signed and Stamped prescribed Form 5 is required. Justification of wheat flour as health product. Long term and accelerated stability studies data is required according to conditions of Zone IV A. COA of finished product is required. Last inspection report/GMP certificate is required.
436.	Nurtulac Wheat-Milk	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> Signed and Stamped prescribed Form 5 is required. Justification of wheat flour as health product. Long term and accelerated stability studies data is required according to conditions of Zone IV A. COA of finished product is required. Last inspection report/GMP certificate is required.
437.	Nurtulac (Rice-Milk)	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> Signed and Stamped prescribed Form 5 is required. Justification of wheat flour as health product. Long term and accelerated stability studies data is required according to conditions of Zone IV A. COA of finished product is required. Last inspection report/GMP certificate is required.
438.	Nurtulac (Wheat-Milk-Honey)	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> Signed and Stamped prescribed Form 5 is required.

S.No	Brand name	Decision
(1)	(2)	(3)
		<ul style="list-style-type: none"> • Justification of wheat flour as health product. • Long term and accelerated stability studies data is required according to conditions of Zone IV A. • COA of finished product is required. • Last inspection report/GMP certificate is required.
439.	Nurtumil LF	EEC was apprised that Division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the Division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of Division of Health & OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
M/s Ghazi Brothers, located at the address Ghazi House D-35, KDA Scheme, No.1, Miran Muhammad Shah Road, Karachi agent of M/s MK BIO Science Co., Inc, 175 Shinnaera, 695 beon-gil, Geumwang-ro, Eumsung-gun, Chungcheongbuk-do, Korea (E. No. 00906)		
440.	Allicom S	<p>Deferred with final opportunity for the submission of following documents:</p> <ul style="list-style-type: none"> • Evidence is required either Korea Feed ingredients association is concerned government regulatory authority and also authorized to issue free sale certificate or otherwise. • Long term stability studies data stating chemical assay of each active ingredients and physical testing premeasures/profile are required. COA of finished product is required.
M/s Jawad Impex International, 21-Iftikhar Building, Chouburji, Lahore agent of M/s Zagro Singapore Pte Ltd Zagro Global Hub 5 Woodlands Terrace Singapore 738460 (E. No. 00113)		
441.	Litter Pro	<p>Deferred with final opportunity for the provision of following documents:</p> <ul style="list-style-type: none"> • Specific speics strain of each probiotics is required. • Testing specification and characterization of probiotics is required. • Perscribed Form 5 is required. • COA of finished product to be issued by principal manufacturer is required. In this case Parific Lab Services, Singapore has issued COA of finished product. Evidence is required stating principal manufacturer has authorized the later to issued COA of finished product. • Stability Studies data Little pro to be issued by principal manufacturer is required. In this case Parific Lab Services, Singapore has issued Stability Studies data of said product Evidence is required stating principal manufacturer has authorized the later to issue Stability Studies data of said product. In this regards principal manufacturer required to provide stability studies data stating microbiological testing profile of said product. • GMP Certificate, Free Sale Certificate, Manufacturing License are not attested and countersigned by the Embassy of Pakistan in country of origin.
M/s Pak Care International Company, located at the address P-26, Al-Qadir Garden, 203 R.B, Mananwala, Faisalabad		
442.	Esel 20% Plus Betain	EEC was apprised that Division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the Division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of Division of Health & OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.

S.No (1)	Brand name (2)	Decision (3)
443.	Vitasupra Mycobond	EEC was apprised that Division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the Division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of Division of Health & OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
444.	Revitamin Premix	EEC was apprised that Division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the Division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of Division of Health & OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
M/s Otsuka Pakistan Ltd, Factory No. F/4-9, Hub Industrial Trading Estate, Distt. Lasbella, Balochistan agent of M/s PT. Otsuka Indonesia, Jl. Sumber Waras No. 25, Lawang, Malang 65216, INDONESIA (E. No. 00239)		
445.	Proten Gold Vanilla	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> • Form is missing. • Master formula is provided, however unit dose formula is not provided. • Long term and accelerated stability studies data is required according to conditions of Zone IV A. • Undertakings are not provided • Clinical studies data is not provided. • The official monographs of the active materials are not provided • Free sale certificate provided is not notarized and counter signed by the Embassy of Pakistan in the country of origin. • GMP Certificate and last inspection issued by the regulatory body in the country of origin is required. • Pack size is not provided.
Eon Pharmacy, Karachi		
446.	Dormir Syrup 20Ml	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> • The applied formulation contains Melatonin which is in the list of common molecule and deferred till the finalization of policy decision
447.	Ivy Kuff Plus Syrup 120Ml	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> • Brand name needs to be changed • Evidence of fee submission is required
448.	Oxyn Tablet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> • Brand name needs to be changed • Evidence of fee submission is required
449.	Oxyn Syrup	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> • Brand name needs to be changed • Evidence of fee submission is required

S.No	Brand name	Decision
(1)	(2)	(3)
450.	Peptec Syrup 120MI	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> The applied formulation contains Sodium bicarbonate which is in the list of common molecule and deferred till the finalization of common molecule list Brand name needs to be changed
Kint Laboratories, Rawalpindi		
451.	Solment Oral Solution	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
452.	Aminokolin Oral Liquid	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
453.	Stress Kill	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
454.	Lactoprime	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
455.	Vioromune Oral Liquid	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> Brand name needs to be changed
Meal Neutricia, Peshawar		
456.	Vita-Cal Tablet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> Brand name needs to be changed
457.	M-Fol Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.

S.No	Brand name	Decision
(1)	(2)	(3)
Mediformers Nutraceutical, Lahore		
458.	Riomen Capsule	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
Mod Herbs, Karachi		
459.	Multifol-Z Tablet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> • Brand name needs to be changed
460.	Natogin Syrup	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> • Brand name needs to be changed • Monograph of Bacopa Moneri ext is required
MSG Nutraceuticals, Islamabad		
461.	Neurobild Tablt	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> • Brand name needs to be changed • Strength of elemental Folic acid in L-methyl folate is required according to RD value
462.	Cuflow Cough Syrup	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> • Properly filled signed and stamped form 3 is required • Brand name needs to be changed
463.	Rose-D Tablet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> • Monograph of Oyster shell calcium is required • Brand name needs to be changed
464.	Care-Folate Tablet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> • Properly filled signed and stamped form 3 is required • Brand name needs to be changed
465.	Cuflow Drops	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> • Properly filled signed and stamped form 3 is required • Brand name needs to be changed
466.	Carycid Tablet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> • Properly filled signed and stamped form 3 is required • Brand name needs to be changed
Neu Mex Healthcare Laboratories, Karachi		
467.	Bestage Tablet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> • Evidence of fee submission is required • Brand name needs to be changed
468.	Bestage Syrup	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> • Evidence of fee submission is required • Brand name needs to be changed
469.	Hemoson Tablet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> • Evidence of fee submission is required • Brand name needs to be changed

S.No	Brand name	Decision
(1)	(2)	(3)
470.	Contized Syrup	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> Firm uses herbs in crude form while possessing nutraceutical facility The applied formulation contains source of (Berberine) which is toxic alkaloids in applied strength
471.	Silkyfol Tablet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> Evidence of fee submission is required Brand name needs to be changed
Neutra Cure, Karachi		
472.	Ginkgo-B Syrup	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
Nutrifactor Laboratories (Pvt) Ltd, Faisalabad		
473.	Vitamax Syrup	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> Brand name needs to be changed
474.	Visionex Syrup	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> Brand name needs to be changed
475.	Bestavit Powder	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> Brand name needs to be changed
476.	Nusitol Powder	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> The applied formulation contains N-acetyl cysteine which is in the list of common molecule and deferred till the finalization of policy decision
Oasis Pharma, Lahore		
477.	Hyrich Food Supplement	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> Properly filled signed and stamped form 3 is required Type of protein/amino acid used in the formulation
478.	Devio+ Tablet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> Properly filled signed and stamped form 3 is required Evidence of fee submission and R&I receiving is required
479.	Zecoplan Food Supplement	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
480.	Mender-24 Suspension	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list.

S.No	Brand name	Decision
(1)	(2)	(3)
		Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
481.	Xairofer Tablet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> • Properly filled signed and stamped form 3 is required • Evidence of fee submission and R&I receiving is required
482.	Mender-24 Capsule	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
483.	Kamzen Ds Tablet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> • The applied formulation contains Serrapeptase which is in the list of common molecule and deferred till the finalization of policy decision
484.	Xairofer Syrup	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> • Properly filled signed and stamped form 3 is required • Evidence of fee submission and R&I receiving is required
485.	Z Mag Tablet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> • Properly filled signed and stamped form 3 is required • Evidence of fee submission and R&I receiving is required
486.	D-Ostelin Drops	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> • Properly filled signed and stamped form 3 is required • Evidence of fee submission and R&I receiving is required
487.	D-Ostelin Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
488.	Lexica Syrup	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> • The applied formulation contains Sennoside A and B which is in the list of common molecule • Monograph of Cuscuta Reflexa and Rheum Palmatum extract are required • Brand name needs to be changed
Otsuka Pakistan Ltd., Karachi		
489.	Rehydrol Ors	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> • The applied product contains ORS formulation which is in the list of common molecule and deferred till the finalization of policy decision
Pakistan Pharmaceutical Products Pvt Ltd, Karachi		

S.No	Brand name	Decision
(1)	(2)	(3)
490.	Laxaprune Syrup	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
491.	Gonegas Syrup	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
492.	Oxamin Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
Phytocon International Private Limited, Lahore		
493.	Bonree Tablet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> • Brand name needs to be changed
494.	Anosam Syrp	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> • Firm uses herbs in crude form • Confirmation of herbal syrup section
495.	Sammax Tablet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> • Evidence of fee submission along with R&I receiving is required
496.	Comug- 10 Tablets	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
Phytotia Laboratory, Peshawar		
497.	Maxonin Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
498.	Phytozyme Syrup	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent

S.No (1)	Brand name (2)	Decision (3)
		preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
499.	Orthomax-D Syrup	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> Properly filled signed and stamped form 3 is required Brand name needs to be changed
Salbion Health Sciences Pvt Ltd, Lahore		
500.	Methyl-F Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
501.	Cal Mix K Tablet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> Properly filled signed and stamped form 3 is required Brand name needs to be changed
502.	Folimac Tablet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> Properly filled signed and stamped form 3 is required Brand name needs to be changed
503.	Disis-G Tablet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> The applied formulation contains Glucosamine and chondroitin which are in the list of common molecule
504.	Benzyn-Ds Tablet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> The applied formulation contains Serratiopeptidase which is in the list of common molecule
505.	Cerogin Tablet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> Brand name needs to be changed
506.	Previt-M Tablet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> Brand name needs to be changed
Saviour Pharma, Lahore		
507.	Calsab Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
Simbro HealthCare, Lahore		
508.	Renacit-K 5Mg Tablet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> The applied formulation contains Potassium citrate which is in the list of common molecule and deferred till the finalization of policy decision

S.No (1)	Brand name (2)	Decision (3)
509.	Renacit-K 10Mg Tablet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> The applied formulation contains Potassium citrate which is in the list of common molecule and deferred till the finalization of policy decision
510.	Alpha Q10 Tablet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> Monograph of Eggplant extract is required Brand name needs to be changed
511.	Urocai Sachet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> Brand name needs to be changed Monograph of Acaiberry juice extract is required
Sois Life Sciences, Karachi		
512.	Pregnoease Tablet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> Brand name needs to be changed
513.	Optibrain 3 Syrup	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> Brand name needs to be changed Monograph of Brahmi extract is required
514.	Softical Plus Tablet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> Brand name needs to be changed Evidence of fee submission and R & I receiving is required
515.	Nutra-L Syrup	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> Brand name needs to be changed Evidence of fee submission and R & I receiving is required
516.	Nutra Active Syrup	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> Brand name needs to be changed Evidence of fee submission and R & I receiving is required
517.	Cranbex Sf Sachet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> Brand name needs to be changed Evidence of fee submission and R & I receiving is required
518.	Cranbex Sachet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> Brand name needs to be changed Evidence of fee submission and R & I receiving is required
519.	Cophodox Syrup	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> Brand name needs to be changed Firm uses herbs in crude form Confirmation of herbal syrup section
520.	3D Drops	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> Brand name needs to be changed Evidence of fee submission and R & I receiving is required
521.	Bresol Syrup	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> Brand name needs to be changed Monograph of Hyssopus officinal is required
Theramed Healthcare, Lahore		
522.	Kolica Drops	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> Brand name needs to be changed Firm uses herbs in crude form

S.No	Brand name	Decision
(1)	(2)	(3)
		<ul style="list-style-type: none"> Confirmation of herbal liquid section Revised form 3 w.r.t specification and strength of active ingredients is required
523.	Penta Syrup	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> Brand name needs to be changed
524.	Kolica Syrup	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> Brand name needs to be changed
Vital Phyto Pharma (Pvt) Ltd, Rawalpindi		
525.	Sangovit Syrup	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
526.	V-Tizer Syrup	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> Firm uses herbs in crude form Confirmation of herbal syrup section Brand name needs to be changed
527.	Ice Touch Syrup	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> Brand name needs to be changed
528.	Coff Off Syrup	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> Brand name needs to be changed
529.	Sangovit Syrup	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> Brand name needs to be changed
530.	Ginseed Extra Syrup	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> Brand name needs to be changed Monograph of Omega 9 is required
531.	Gastonil Suspensionn	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> Brand name needs to be changed The applied formulation contains Sodium bicarbonate which is in the list of common molecule
532.	Vital Forte Syrup	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> Brand name needs to be changed
533.	Complex-N Food Supplement	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> Confirmation of food supplement section is required
534.	Ibf Neo Syrup	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> Brand name needs to be changed
535.	Neurofast Sryup	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> Firm uses herbs in crude form Confirmation of herbal syrup section Brand name needs to be changed

S.No	Brand name	Decision
(1)	(2)	(3)
Well Grow Nutraceuticals Faisalabad		
536.	Re-Virg Tablet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> Firm uses herbs in crude form Confirmation of Herbal tablet section
537.	Multicomplex-M Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
538.	Lecare Tablet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> Firm uses herbs in crude form Confirmation of Herbal tablet section Brand name needs to be changed
539.	Medimax-H Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
540.	Medimax-M Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
541.	Multicomplex-Z Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
542.	Vcal-D Drops	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> Brand name needs to be changed
543.	Kof-X Syrup	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> Brand name needs to be changed Firm uses herbs in crude form Confirmation of Herbal syrup section
544.	Medimax-Z Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications

S.No (1)	Brand name (2)	Decision (3)
		were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
545.	Spazisa Syrup	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> Brand name needs to be changed Firm uses herbs in crude form Confirmation of Herbal syrup section
546.	Medimax-T Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
547.	Poly Iron Tablet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> Brand name needs to be changed
Wilson's Healthcare, Islamabad		
548.	Seacal-Sf Effervescent Tablet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> Properly filled signed and stamped form 3 is required Undertaking regarding content and brand name is required Brand name needs to be changed
549.	Plantcal-Sf Effervescent Tablet (Lemon Flavor)	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> Properly filled signed and stamped form 3 is required Undertaking regarding content and brand name is required Brand name needs to be changed Monograph of Calcium Red algae is required Strength of Iodine, Manganese ,Boron and Potassium is required
550.	Daily Cal Sf Effervescent Tablet (Lemon Flavor)	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> Properly filled signed and stamped form 3 is required Undertaking regarding content and brand name is required Brand name needs to be changed Monograph of Calcium Red algae is required Strength of Iodine, Manganese ,Boron and Potassium is required
Zonex Pharma (Pvt) Ltd, Lahore		
551.	Aletis Corcial Syrup	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> Brand name needs to be changed Firm uses herbs in crude form while possessing nutraceutical facility
552.	Holcin Ds Tablet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> The applied formulation contains Serratiopeptidase which is in the list of common molecule
Adcok Pharmaceutical (Pvt) Ltd, Lahore		
553.	Zeforce Syrup	Deferred till finalization of common molecules list (melatonin).
554.	Prime Leaf Syrup	Deferred for following reasons: <ul style="list-style-type: none"> Monograph of solanum xanthocarpum extract, terminalia belerica exyteact, ocimum sanctum extract are required. Brand name to be changed.
555.	Melakid Drops	Deferred till finalization of common molecules list (melatonin).

S.No (1)	Brand name (2)	Decision (3)
M/s. Blossom Laboratories (Pvt.) Ltd., 30-KM, Badian Road, ½ K.M Off Roda Bohgal Road, Lahore Cant (00181)		
556.	Cure-Mate Tablet	EEC decided to defer the application for enlistment due to following reasons: The applied formulation contains Aescin which is common molecule and deferred till the finalization of policy decision
557.	Fabize Syrup	EEC decided to defer the application for enlistment due to following reasons: The applied formulation contains Zinc sulphate as a single ingredient which is common molecule and deferred till the finalization of policy decision
558.	Fabize Drops	EEC decided to defer the application for enlistment due to following reasons: The applied formulation contains Zinc sulphate as a single ingredient which is common molecule and deferred till the finalization of policy decision
559.	Ezibid Drops	EEC decided to defer the application for enlistment due to following reasons: The applied formulation contains B-D-Galactosidase which is common molecule and deferred till the finalization of policy decision
560.	Sipep Tablet	EEC decided to defer the application for enlistment due to following reasons: The applied formulation contains Serratiopeptidase which is common molecule and deferred till the finalization of policy decision
Al-Ain Nutro, 12D/A Peco road, Kotlakpat Industrail Estate, Lahore		
561.	Apirise Syrup	Deferred for following reasons: • Monograph of gentian extract, angelica extract are required. • Brand name to be changed.
562.	Amocid Syrup (Mint)	Deferred till finalization of common molecules list (sodium bicarbonate).
563.	Hemachel Syrup	Deferred for change of brand name.
564.	Brilian Tablet	Deferred for change of brand name.
Alfalah Health Care (Pvt) Ltd Lahore		
565.	Velvy Syrup	Deferred for following reasons: • Form 3 is required. • Evidence of fee challan and R&I receiving is required. • Undertaking regarding brand name change and contents of dossier are required.
Ali's Pakistan, Lahore		
566.	Apimore Syrup	Deferred for submission of Monographs of gentian extract, angelica extract and change of brand name.
Arber Pharma, Lahore		
567.	Kof-Mark Syrup	Deferred for following reasons: • Form 3 is required. • Evidence of fee challan and R&I receiving is required. • Undertaking regarding brand name change and contents of dossier are required.
568.	Silnor Capsule	Deferred for following reasons: • Form 3 is required. • Evidence of fee challan and R&I receiving is required. • Undertaking regarding brand name change and contents of dossier are required.
569.	Strong Bon-D3 Tablet	Deferred for following reasons: • Form 3 is required. • Evidence of fee challan and R&I receiving is required. • Undertaking regarding brand name change and contents of dossier are required.
570.	Glote Syrup	Deferred for following reasons: • Form 3 is required. • Evidence of fee challan and R&I receiving is required.

S.No (1)	Brand name (2)	Decision (3)
		<ul style="list-style-type: none"> Undertaking regarding brand name change and contents of dossier are required.
571.	Coolcid Syrup	Deferred for following reasons: <ul style="list-style-type: none"> Form 3 is required. Evidence of fee challan and R&I receiving is required. Undertaking regarding brand name change and contents of dossier are required.
Arshzik Pharma, Rawalpindi		
572.	Milko Tech Powder	Deferred for change of brand name.
573.	Zinselvite E Oral Liquid	Deferred for following reasons: <ul style="list-style-type: none"> Form 3 is required. Evidence of fee challan and R&I receiving is required. Undertaking regarding brand name change and contents of dossier are required.
574.	Fibro Tech Oral Liquid	Deferred for submission of Monographs of all ingredients in extract form.
575.	Temso Tech Oral Liquid	Deferred for submission of Monographs of all ingredients in extract form.
576.	Bio Livo Tech	Deferred for following reasons: <ul style="list-style-type: none"> Form 3 is required. Evidence of fee challan and R&I receiving is required. Undertaking regarding brand name change and contents of dossier are required.
Asfar Healthcare, Kasur		
577.	Hi-Lactomil Capsule	Deferred for change of brand name.
578.	Ivy Rex Syrup	Deferred till finalization of common molecules list and change of brand name.
Atco HealthCare Pvt Ltd, Karachi		
579.	Rehto Eye Drop	Deferred for following reasons: <ul style="list-style-type: none"> Form 3 is required. Evidence of fee challan and R&I receiving is required. Undertaking regarding brand name change and contents of dossier are required.
580.	Nojerm Ointment	Deferred for following reasons: <ul style="list-style-type: none"> Form 3 is required. Evidence of fee challan and R&I receiving is required. Undertaking regarding brand name change and contents of dossier are required.
581.	Abeaz Oral Liquid	Deferred for following reasons: <ul style="list-style-type: none"> Form 3 is required. Evidence of fee challan and R&I receiving is required. Undertaking regarding brand name change and contents of dossier are required.
Aulton Nutraceuticals, Hattar		
582.	Frutavit-M Syrup	Deferred for change of brand name.
Aurum Health Care, Lahore		
583.	Active X Plus Tablet	Deferred for following reasons: <ul style="list-style-type: none"> Form 3 is required. Evidence of fee challan and R&I receiving is required. Undertaking regarding brand name change and contents of dossier are required.
Avanza Health Care Pvt Ltd, Lahore		
584.	Colezal-Ivy Syrup	Deferred for following reasons: <ul style="list-style-type: none"> Form 3 is required. Evidence of fee challan and R&I receiving is required. Undertaking regarding brand name change and contents of dossier are required.
Bio Life Enterprises Nutraceuticals, Rawalpindi		
585.	Uresol Sachet	Deferred for following reasons: <ul style="list-style-type: none"> Form 3 is required.

S.No (1)	Brand name (2)	Decision (3)
		<ul style="list-style-type: none"> Evidence of fee challan and R&I receiving is required. Undertaking regarding brand name change and contents of dossier are required.
586.	Mam2B Supplement	Deferred for following reasons: <ul style="list-style-type: none"> Availability of food supplement section is required. Strength of each ingredient per serving dose to be rationed according to respective RDA limit. Brand name to be changed. Fee evidence is required.
Bio Serve Pharma, Karachi		
587.	Mac-F Plus Tablet	Deferred for following reasons: <ul style="list-style-type: none"> Form 3 is required. Evidence of fee challan and R&I receiving is required. Undertaking regarding brand name change and contents of dossier are required.
Bio-Med Pharma, Karachi		
588.	Dice G Tablet	Deferred for following reasons: <ul style="list-style-type: none"> Form 3 is required. Evidence of fee challan and R&I receiving is required. Undertaking regarding brand name change and contents of dossier are required.
589.	Megwel Tablet	Deferred for following reasons: <ul style="list-style-type: none"> Form 3 is required. Evidence of fee challan and R&I receiving is required. Undertaking regarding brand name change and contents of dossier are required.
590.	Comeg-Junior	Deferred for following reasons: <ul style="list-style-type: none"> Form 3 is required. Evidence of fee challan and R&I receiving is required. Undertaking regarding brand name change and contents of dossier are required.
Bion Life Sciences, Lahore		
591.	Q Vital Capsule	Deferred for following reasons: <ul style="list-style-type: none"> Form 3 is required. Evidence of fee challan and R&I receiving is required. Undertaking regarding brand name change and contents of dossier are required.
592.	Prolate-Hb Syrup	Deferred for following reasons: <ul style="list-style-type: none"> Form 3 is required. Evidence of fee challan and R&I receiving is required. Undertaking regarding brand name change and contents of dossier are required.
593.	Biowomen Capsule	Deferred for following reasons: <ul style="list-style-type: none"> Availability of herbal capsule section is required. Brand name needs to be changed. Monograph of vitex agnus castus is required.
Bless Laboratories Pvt. Ltd., Lahore		
594.	Brainova X Tablet	Deferred for change of brand name.
595.	Raftar Moringa Capsule	Deferred for change of brand name.
596.	Sewnli Tablet	Deferred till finalization of common molecules list (Seritiopeptidase).
597.	Fabize Drops	Deferred till finalization of common molecules list (zinc sulphate as single ingredient).
598.	Q Star Tablet	Deferred for change of brand name.
599.	Silstar Tablet	Deferred for following reasons: <ul style="list-style-type: none"> Silymarin is added in common molecules list. Monograph of L-ornithine is required.
600.	Brainova Tablet	Deferred for following reasons:

S.No (1)	Brand name (2)	Decision (3)
		<ul style="list-style-type: none"> Monograph of alpha GPC is required. Brand name to be changed.
Calgan Phyto Pharma Pvt Ltd, Lahore		
601.	Bonwin Tablet	Deferred for following reasons: <ul style="list-style-type: none"> Brand name to be changed. Monograph of red fruit juice blend is required.
602.	Mesomac Tablet	Deferred for submission of Individual strength of lutein and zeaxanthin.
603.	Rospan Liquid	Deferred for change of brand name.
604.	Pain-Go Gel	Deferred for following reasons: <ul style="list-style-type: none"> Brand name to be changed. Glucosamine and capsaicin are added in common molecules list.
605.	Vitobex Liquid	Deferred for submission of Monographs of chlorophyll (from mulberry leaf) and chorella regularis.
606.	Co-Mint Liquid	Deferred for submission of Monograph of catnip extract.
607.	Mucan Sachet	Deferred for change of brand name.
608.	Zelco Sachet	Deferred for following reasons: <ul style="list-style-type: none"> Justification of fructose as health product is required. Monograph of L-carnitine fumarate and acetyl L-carnitine are required.
609.	Calsip-D Tablet	Deferred for following reasons: <ul style="list-style-type: none"> Form 3 is required. Evidence of fee challan and R&I receiving is required. Undertaking regarding brand name change and contents of dossier are required.
610.	Calif-D Tablet	Deferred for following reasons: <ul style="list-style-type: none"> Form 3 is required. Evidence of fee challan and R&I receiving is required. Undertaking regarding brand name change and contents of dossier are required.
611.	Armax Liquid Herbal Ext	Deferred for following reasons: <ul style="list-style-type: none"> Form 3 is required. Evidence of fee challan and R&I receiving is required. Undertaking regarding brand name change and contents of dossier are required.
Cidex Laboratories, Peshawar		
612.	Sebugin-E Capsule	Deferred for submission of Monograph of pausynstalia yohimbe extract.
613.	Farovit-M	Deferred for change of brand name.
614.	Viptal Forte Capsule	Deferred for change of brand name.
Classic Nutraceutical Labs, Peshawar		
615.	Carmisel Syrup	Deferred for submission of Monograph of valerian extract.
616.	Dura Flush Powder	Deferred till finalization of common molecules list.
617.	Ft-Flush Powder	Deferred till finalization of common molecules list.
618.	Heptacure Liquid	Deferred till finalization of common molecules list.
619.	Multiplex Liquid	Deferred for change of brand name.
Cosmo Pharma International Pvt Ltd, Karachi		
620.	Silkyfol Tablet	Deferred for change of brand name.
Crystolite Pharmaceuticals, Islamabad		
621.	Cholset Syrup	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is of tummy set syrup while applied product is cholset syrup, needs justification in this regard. According to nutraceutical FIFO list at serial no. 10472, brand name is cholset while fee challan of said product is not provided.
Dolphin Laboratories, Lahore		

S.No (1)	Brand name (2)	Decision (3)
622.	D-Stop Syrup	Deferred for following reasons: <ul style="list-style-type: none"> Kaolin is added in common molecules list. Monograph of oak extract and pectin are required. Brand name to be changed.
623.	Colic-D Syrup	Deferred for change of brand name.
624.	Colic-D Drop	Deferred for change of brand name.
625.	Depol Tablet	Deferred for following reasons: <ul style="list-style-type: none"> Monograph of onosma bracteatum extract, sisymbrium officinale extract and zizyphus jujube extract are required. Brand name to be changed.
626.	Depol Syrup	Deferred for following reasons: <ul style="list-style-type: none"> Monograph of onosma bracteatum extract, sisymbrium officinale extract and zizyphus jujube extract are required. Brand name to be changed.
627.	D-Crack Cream	Deferred for following reasons: <ul style="list-style-type: none"> Form 3 is required. Evidence of fee challan and R&I receiving is required. Undertaking regarding brand name change and contents of dossier are required.
628.	Spasmodol Syrup	Deferred for following reasons: <ul style="list-style-type: none"> Monographs of all ingredients in extract form are required. Brand name to be changed.
629.	Fludol Cf Tablet	Deferred for following reasons: <ul style="list-style-type: none"> Form 3 is required. Evidence of fee challan and R&I receiving is required. Undertaking regarding brand name change and contents of dossier are required.
630.	Fludol Syrup	Deferred for change of brand name.
631.	Multi-Box Tablet	Deferred for change of brand name.
632.	Hyo-C Plus Tablet	Deferred till finalization of common molecules list and change of brand name.
633.	Kuffix Syrup	Deferred for change of brand name.
634.	Davi-Plus Syrup	Deferred till finalization of common molecules list and change of brand name.
Genetics Healthcare, Lahore		
635.	Flamicure Sr Capsule	Deferred for following reasons: <ul style="list-style-type: none"> Monograph of curcumin sustained release complex is required. Manufacturing method of sustained release method of said product is required. Justification of sustained release product is required. Brand name needs to be changed.
636.	Sevetol Sr Capsule	Deferred for following reasons: <ul style="list-style-type: none"> Form 3 is required. Evidence of fee challan and R&I receiving is required. Undertaking regarding brand name change and contents of dossier are required.
Glitz Healthcare, Islamabad		
637.	Bvit Tablet	Deferred for change of brand name.
638.	G-Bone Plus Tablet	Deferred for following reasons: <ul style="list-style-type: none"> Form 3 is required. Evidence of fee challan and R&I receiving is required. Undertaking regarding brand name change and contents of dossier are required.
639.	G-Tone Tablet	Deferred for change of brand name.

S.No (1)	Brand name (2)	Decision (3)
640.	G-Bone Tablet	Deferred for change of brand name.
641.	Multivit Tablet	Deferred for change of brand name.
642.	G Care Supplement	Deferred for following reasons: <ul style="list-style-type: none"> Form 3 is required. Evidence of fee challan and R&I receiving is required. Undertaking regarding brand name change and contents of dossier are required.
643.	Active D3 Syrup	Deferred for change of brand name.
644.	Gli Kuff Syrup	Deferred for change of brand name.
645.	Glitz-Lax Syrup	Deferred for change of brand name.
646.	Multivit-G Syrup	Deferred for change of brand name.
647.	Glicid Syrup	Deferred till finalization of common molecules list.
648.	Vitaliz Plus Tablet	Deferred for change of brand name.
649.	Glitz Gripe Water	Deferred till finalization of common molecules list.
Glorious Laboratories, Islamabad		
650.	Hi-Zink Oral Liquid	Deferred for following reasons: <ul style="list-style-type: none"> Form 3 is required. Evidence of fee challan and R&I receiving is required. Undertaking regarding brand name change and contents of dossier are required.
651.	Gi-Care Syrup	Deferred for following reasons: <ul style="list-style-type: none"> Form 3 is required. Evidence of fee challan and R&I receiving is required. Undertaking regarding brand name change and contents of dossier are required.
652.	Naphro Syrup	Deferred for following reasons: <ul style="list-style-type: none"> Form 3 is required. Evidence of fee challan and R&I receiving is required. Undertaking regarding brand name change and contents of dossier are required.
653.	Neuromeg Tablet	Deferred for change of brand name.
654.	Neuromeg Syrup	Deferred for change of brand name.
655.	Calfit-D Syrup	Deferred for change of brand name.
656.	Calfit-D Tablet	Deferred for change of brand name.
Gold Sheff International, 537-F, Sundar Industrial Estate, Raiwind Road, Lahore		
657.	Gold Plex Syrup	Deferred for following reasons: <ul style="list-style-type: none"> Form 3 is required. Evidence of fee challan and R&I receiving is required. Undertaking regarding brand name change and contents of dossier are required.
658.	D-Gold Tablet	Deferred for following reasons: <ul style="list-style-type: none"> Form 3 is required. Evidence of fee challan and R&I receiving is required. Undertaking regarding brand name change and contents of dossier are required.
659.	Cimitac Tablet	Deferred for following reasons: <ul style="list-style-type: none"> Form 3 is required. Evidence of fee challan and R&I receiving is required. Undertaking regarding brand name change and contents of dossier are required.
660.	Bonium Ds Tablet	Deferred for following reasons: <ul style="list-style-type: none"> Form 3 is required. Evidence of fee challan and R&I receiving is required. Undertaking regarding brand name change and contents of dossier are required.
661.	Softina Tablet	Deferred for following reasons: <ul style="list-style-type: none"> Form 3 is required. Evidence of fee challan and R&I receiving is required. Undertaking regarding brand name change and contents of dossier are required.

S.No	Brand name	Decision
(1)	(2)	(3)
662.	Laxodyl Syrup	Deferred for following reasons: <ul style="list-style-type: none"> Form 3 is required. Evidence of fee challan and R&I receiving is required. Undertaking regarding brand name change and contents of dossier are required.
663.	Cofse Tablet	Deferred for following reasons: <ul style="list-style-type: none"> Form 3 is required. Evidence of fee challan and R&I receiving is required. Undertaking regarding brand name change and contents of dossier are required.
664.	Ostofit Plus Tablet	Deferred for following reasons: <ul style="list-style-type: none"> Form 3 is required. Evidence of fee challan and R&I receiving is required. Undertaking regarding brand name change and contents of dossier are required.
Greens Natural Care, 22km Off Ferozpur road, Lahore		
665.	Dolorub Gel	Deferred for following reasons: <ul style="list-style-type: none"> Form 3 is required. Evidence of fee challan and R&I receiving is required. Undertaking regarding brand name change and contents of dossier are required.
666.	E-Z Gel	Deferred for following reasons: <ul style="list-style-type: none"> Form 3 is required. Evidence of fee challan and R&I receiving is required. Undertaking regarding brand name change and contents of dossier are required.
667.	Cary Sachet	Deferred for following reasons: <ul style="list-style-type: none"> Form 3 is required. Evidence of fee challan and R&I receiving is required. Undertaking regarding brand name change and contents of dossier are required.
Hinucon, Karachi		
668.	Hil-B Softgel Capsule	Deferred for following reasons: <ul style="list-style-type: none"> Form 3 is required. Evidence of fee challan and R&I receiving is required. Undertaking regarding brand name change and contents of dossier are required.
669.	Falvina Softgel Capsule	Deferred for following reasons: <ul style="list-style-type: none"> Form 3 is required. Evidence of fee challan and R&I receiving is required. Undertaking regarding brand name change and contents of dossier are required.
670.	Fermro Softgel Capsule	Deferred for following reasons: <ul style="list-style-type: none"> Form 3 is required. Evidence of fee challan and R&I receiving is required. Undertaking regarding brand name change and contents of dossier are required.
671.	Hilvot Softgel Capsule	Deferred for following reasons: <ul style="list-style-type: none"> Form 3 is required. Evidence of fee challan and R&I receiving is required. Undertaking regarding brand name change and contents of dossier are required.
672.	Pumro Softgel Capsule	Deferred for following reasons: <ul style="list-style-type: none"> Form 3 is required. Evidence of fee challan and R&I receiving is required. Undertaking regarding brand name change and contents of dossier are required.
673.	Hana Softgel Capsule	Deferred for following reasons: <ul style="list-style-type: none"> Form 3 is required. Evidence of fee challan and R&I receiving is required.

S.No	Brand name	Decision
(1)	(2)	(3)
		<ul style="list-style-type: none"> Undertaking regarding brand name change and contents of dossier are required.
674.	Guarmax Jar Mint Flavor	Deferred for following reasons: <ul style="list-style-type: none"> Form 3 is required. Evidence of fee challan and R&I receiving is required. Undertaking regarding brand name change and contents of dossier are required.
675.	Valanxa Mint Sachet	Deferred since Melatonin is added in common molecules list.
676.	Menopaz Plus Capsule	Deferred for following reasons: <ul style="list-style-type: none"> Form 3 is required. Evidence of fee challan and R&I receiving is required. Undertaking regarding brand name change and contents of dossier are required.
677.	Profect Tablet	Deferred since Multi enzyme complex (amylase, lactase, protease and natural protease) is added in common molecules list.



(Ayyaz Ahmad)

Secretary, Enlistment Evaluation Committee

ANNEXURE

The firm is directed to submit soft data in both
MS Excel & MS Word on following formats in
USB ONLY.

MS Excel Format

Sr. No.	Company name	Product Name	Dosage Form	Composition	Common name	Recommended use	Pack Size	Date of R&I submission
1.	(Company name, City) Without address	XYZ	Tablet	Each tablet contains: Abc (USP)...50mg	XXX	XXX	10's 20's	DD.MM.YYYY
2.								

MS Word Format

Sr. No.	Company name	Product Name and composition	Common name	Recommended use	Pack Size
1.	(Company name, City) Without address	XYZ Tablet Each tablet contains: Abc (USP)....50mg	XXX	XXX	10's 20's
2.					